

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 10-Q**

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the quarterly period ended March 31, 2019  
OR  
 **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
Commission file number 001-35547

**ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or Other Jurisdiction of  
Incorporation or Organization)

36-4392754  
(I.R.S. Employer  
Identification No.)

222 Merchandise Mart, Suite 2024  
Chicago, IL 60654  
(Address of Principal Executive Offices, Zip Code)

(800) 334-8534  
(Registrant's Telephone Number, Including Area Code)

**Securities registered pursuant to Section 12(b) of the Act:**

| <u>Title of Each Class</u>               | <u>Trading Symbol</u> | <u>Name of Each Exchange on which Registered</u>             |
|--|-----------------------|--|
| Common Stock, par value \$0.01 per share | MDRX                  | The Nasdaq Stock Market LLC<br>(Nasdaq Global Select Market) |

**Securities registered pursuant to Section 12(g) of the Act: None**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

|                         |                                     |                           |                          |
|-------------------------|-------------------------------------|---------------------------|--------------------------|
| Large accelerated filer | <input checked="" type="checkbox"/> | Accelerated filer         | <input type="checkbox"/> |
| Non-accelerated filer   | <input type="checkbox"/>            | Smaller reporting company | <input type="checkbox"/> |
|                         |                                     | Emerging growth company   | <input type="checkbox"/> |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of May 1, 2019, there were 166,438,125 shares of the registrant's \$0.01 par value common stock outstanding.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

FORM 10-Q

For the Fiscal Quarter Ended March 31, 2019

TABLE OF CONTENTS

|   | <u>PAGE</u> |
|---|-------------|
| <u>PART I. FINANCIAL INFORMATION</u>  | 3           |
| Item 1. <a href="#">Financial Statements (unaudited)</a>  | 3           |
| Item 2. <a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a> | 28          |
| Item 3. <a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>                            | 41          |
| Item 4. <a href="#">Controls and Procedures</a>   | 41          |
| <u>PART II. OTHER INFORMATION</u>   | 42          |
| Item 1. <a href="#">Legal Proceedings</a>   | 42          |
| Item 1.A. <a href="#">Risk Factors</a>  | 42          |
| Item 2. <a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>                           | 42          |
| Item 6. <a href="#">Exhibits</a>  | 43          |
| <u>SIGNATURES</u>   | 44          |

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.  
CONSOLIDATED BALANCE SHEETS  
(Unaudited)

| (In thousands, except per share amounts)   | March 31, 2019      | December 31, 2018   |
|--|---------------------|---------------------|
| <b>ASSETS</b>  |                     |                     |
| Current assets:  |                     |                     |
| Cash and cash equivalents  | \$ 137,167          | \$ 174,243          |
| Restricted cash  | 10,681              | 10,552              |
| Accounts receivable, net of allowance of \$39,214 and \$50,406 as of<br>March 31, 2019 and December 31, 2018, respectively | 457,960             | 465,264             |
| Contract assets  | 95,077              | 66,451              |
| Prepaid expenses and other current assets  | 133,448             | 142,455             |
| Total current assets   | 834,333             | 858,965             |
| Fixed assets, net  | 115,564             | 121,913             |
| Software development costs, net  | 219,047             | 209,660             |
| Intangible assets, net   | 415,437             | 431,081             |
| Goodwill   | 1,373,996           | 1,373,744           |
| Deferred taxes, net  | 4,946               | 5,036               |
| Contract assets - long-term  | 72,042              | 71,879              |
| Right-of-use assets - operating leases   | 97,411              | 0                   |
| Other assets   | 109,632             | 109,206             |
| Total assets   | <u>\$ 3,242,408</u> | <u>\$ 3,181,484</u> |

**ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.**  
**CONSOLIDATED BALANCE SHEETS (CONTINUED)**  
(Unaudited)

| (In thousands, except per share amounts)   | March 31, 2019      | December 31, 2018   |
|--|---------------------|---------------------|
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>  |                     |                     |
| Current liabilities:   |                     |                     |
| Accounts payable   | \$ 80,585           | \$ 73,166           |
| Accrued expenses   | 108,773             | 107,068             |
| Accrued compensation and benefits  | 61,500              | 100,076             |
| Income tax payable   | 0                   | 29,644              |
| Deferred revenue   | 504,089             | 466,797             |
| Current maturities of long-term debt   | 20,518              | 20,059              |
| Current operating lease liabilities  | 24,154              | 0                   |
| Current liabilities attributable to discontinued operations  | 0                   | 920                 |
| <b>Total current liabilities</b>   | <b>799,619</b>      | <b>797,730</b>      |
| Long-term debt   | 766,240             | 647,539             |
| Deferred revenue   | 13,089              | 15,984              |
| Deferred taxes, net  | 58,366              | 58,470              |
| Long-term operating lease liabilities  | 95,112              | 0                   |
| Other liabilities  | 53,865              | 81,334              |
| <b>Total liabilities</b>   | <b>1,786,291</b>    | <b>1,601,057</b>    |
| Commitments and contingencies  |                     |                     |
| Stockholders' equity:  |                     |                     |
| Preferred stock: \$0.01 par value, 1,000 shares authorized,<br>no shares issued and outstanding as of March 31, 2019 and December 31, 2018   | 0                   | 0                   |
| Common stock: \$0.01 par value, 349,000 shares authorized as of March 31, 2019<br>and December 31, 2018; 272,013 and 166,134 shares issued and outstanding as of<br>March 31, 2019, respectively; 270,955 and 171,224 shares issued and outstanding<br>as of December 31, 2018, respectively | 2,719               | 2,709               |
| Treasury stock: at cost, 105,879 and 99,731 shares as of March 31, 2019 and<br>December 31, 2018, respectively   | (525,613)           | (460,543)           |
| Additional paid-in capital   | 1,858,319           | 1,881,494           |
| Retained earnings (accumulated deficit)  | 125,289             | 132,842             |
| Accumulated other comprehensive loss   | (4,597)             | (5,389)             |
| <b>Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity</b>  | <b>1,456,117</b>    | <b>1,551,113</b>    |
| Non-controlling interest   | 0                   | 29,314              |
| <b>Total stockholders' equity</b>  | <b>1,456,117</b>    | <b>1,580,427</b>    |
| <b>Total liabilities and stockholders' equity</b>  | <b>\$ 3,242,408</b> | <b>\$ 3,181,484</b> |

The accompanying notes are an integral part of these consolidated financial statements.

**ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**  
(Unaudited)

| (In thousands, except per share amounts)  | Three Months Ended<br>March 31, |                    |
|---|---------------------------------|--------------------|
|   | 2019                            | 2018               |
| <b>Revenue:</b>   |                                 |                    |
| Software delivery, support and maintenance  | \$ 275,512                      | \$ 280,553         |
| Client services   | 156,537                         | 153,169            |
| Total revenue   | <u>432,049</u>                  | <u>433,722</u>     |
| <b>Cost of revenue:</b>   |                                 |                    |
| Software delivery, support and maintenance  | 88,133                          | 86,010             |
| Client services   | 141,599                         | 137,088            |
| Amortization of software development and acquisition-related assets   | 28,222                          | 25,959             |
| Total cost of revenue   | <u>257,954</u>                  | <u>249,057</u>     |
| Gross profit  | 174,095                         | 184,665            |
| Selling, general and administrative expenses  | 100,245                         | 119,937            |
| Research and development  | 64,310                          | 64,790             |
| Asset impairment charges  | 98                              | 0                  |
| Amortization of intangible and acquisition-related assets   | 6,797                           | 6,639              |
| Income (loss) from operations   | 2,645                           | (6,701)            |
| Interest expense  | (10,184)                        | (11,694)           |
| Other income (loss), net  | 513                             | (35)               |
| Loss on sale of businesses, net   | 0                               | (871)              |
| Recovery (impairment) of long-term investments  | 1,045                           | (5,500)            |
| Equity in net loss of unconsolidated investments  | (64)                            | (61)               |
| Loss from continuing operations before income taxes   | (6,045)                         | (24,862)           |
| Income tax provision  | (1,932)                         | (299)              |
| Loss from continuing operations, net of tax   | (7,977)                         | (25,161)           |
| Loss from discontinued operations   | 0                               | (5,016)            |
| Income tax effect on discontinued operations  | 0                               | 1,662              |
| Loss from discontinued operations, net of tax   | 0                               | (3,354)            |
| Net loss  | (7,977)                         | (28,515)           |
| Net loss attributable to non-controlling interests  | 424                             | 790                |
| Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations | 0                               | (12,149)           |
| Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders                                     | <u>\$ (7,553)</u>               | <u>\$ (39,874)</u> |
| Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share:                          |                                 |                    |
| <b>Basic</b>  |                                 |                    |
| Continuing operations   | \$ (0.04)                       | \$ (0.14)          |
| Discontinued operations   | 0.00                            | (0.08)             |
| Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share                           | <u>\$ (0.04)</u>                | <u>\$ (0.22)</u>   |
| <b>Diluted</b>  |                                 |                    |
| Continuing operations   | \$ (0.04)                       | \$ (0.14)          |
| Discontinued operations   | 0.00                            | (0.08)             |
| Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share                           | <u>\$ (0.04)</u>                | <u>\$ (0.22)</u>   |

The accompanying notes are an integral part of these consolidated financial statements.

**ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**  
(Unaudited)

| (In thousands)   | Three Months Ended<br>March 31, |             |
|--|---------------------------------|-------------|
|  | 2019                            | 2018        |
| Net loss   | \$ (7,977)                      | \$ (28,515) |
| Other comprehensive (loss) income:   |                                 |             |
| Foreign currency translation adjustments   | 695                             | 123         |
| Change in fair value of derivatives qualifying as cash flow hedges                 | 132                             | (633)       |
| Other comprehensive income (loss) before income tax (expense) benefit              | 827                             | (510)       |
| Income tax (expense) benefit related to items in other comprehensive (loss) income | (35)                            | 314         |
| Total other comprehensive income (loss)  | 792                             | (196)       |
| Comprehensive loss   | (7,185)                         | (28,711)    |
| Comprehensive loss attributable to non-controlling interests                       | 424                             | 790         |
| Comprehensive (loss) income, net   | \$ (6,761)                      | \$ (27,921) |

The accompanying notes are an integral part of these consolidated financial statements.

**ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.**  
**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**  
(Unaudited)

| (In thousands)  | Three Months Ended March 31, |                     |
|---|------------------------------|---------------------|
|   | 2019                         | 2018                |
| <b>Number of Common Shares</b>  |                              |                     |
| Balance at beginning of period  | 270,955                      | 269,335             |
| Common stock issued under stock compensation plans, net of shares withheld for employee taxes                   | 1,058                        | 1,266               |
| Balance at end of period  | 272,013                      | 270,601             |
| <b>Common Stock</b>   |                              |                     |
| Balance at beginning of period  | \$ 2,709                     | \$ 2,693            |
| Common stock issued under stock compensation plans, net of shares withheld for employee taxes                   | 10                           | 13                  |
| Balance at end of period  | \$ 2,719                     | \$ 2,706            |
| <b>Number of Treasury Stock Shares</b>  |                              |                     |
| Balance at beginning of period  | (99,731)                     | (88,504)            |
| Issuance of treasury stock  | 0                            | 0                   |
| Purchase of treasury stock  | (6,148)                      | (4,144)             |
| Balance at end of period  | (105,879)                    | (92,648)            |
| <b>Treasury Stock</b>   |                              |                     |
| Balance at beginning of period  | \$ (460,543)                 | \$ (322,735)        |
| Purchase of treasury stock  | (65,070)                     | (57,600)            |
| Balance at end of period  | \$ (525,613)                 | \$ (380,335)        |
| <b>Additional Paid-In Capital</b>   |                              |                     |
| Balance at beginning of period  | \$ 1,881,494                 | \$ 1,781,059        |
| Stock-based compensation  | 11,394                       | 9,935               |
| Common stock issued under stock compensation plans, net of shares withheld for employee taxes                   | (5,338)                      | (8,296)             |
| Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations | 0                            | (12,149)            |
| Subsidiary issuance of common stock   | 0                            | (430)               |
| Warrants issued   | 682                          | 682                 |
| Acquisition of non-controlling interest   | (29,913)                     | 0                   |
| Balance at end of period  | \$ 1,858,319                 | \$ 1,770,801        |
| <b>Retained earnings (accumulated deficit)</b>  |                              |                     |
| Balance at beginning of period  | \$ 132,842                   | \$ (338,150)        |
| Net loss less net income attributable to non-controlling interests  | (7,553)                      | (27,725)            |
| ASC 606 implementation adjustments  | 0                            | 46,604              |
| Balance at end of period  | \$ 125,289                   | \$ (319,271)        |
| <b>Accumulated Other Comprehensive Loss</b>   |                              |                     |
| Balance at beginning of period  | \$ (5,389)                   | \$ (1,985)          |
| Foreign currency translation adjustments, net   | 695                          | 123                 |
| Unrecognized gain on derivatives qualifying as cash flow hedges, net of tax                                     | 97                           | (319)               |
| Balance at end of period  | \$ (4,597)                   | \$ (2,181)          |
| <b>Non-controlling interest</b>   |                              |                     |
| Balance at beginning of period  | \$ 29,314                    | \$ 39,190           |
| Acquisition of non-controlling interest   | (28,890)                     | 0                   |
| Net loss attributable to non-controlling interests  | (424)                        | (790)               |
| Balance at end of period  | \$ 0                         | \$ 38,400           |
| <b>Total Stockholders' Equity at beginning of period</b>  | <b>\$ 1,580,427</b>          | <b>\$ 1,160,072</b> |
| <b>Total Stockholders' Equity at end of period</b>  | <b>\$ 1,456,117</b>          | <b>\$ 1,110,120</b> |

The accompanying notes are an integral part of these consolidated financial statements.

**ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Unaudited)

| (In thousands)   | Three Months Ended March 31, |             |
|--|------------------------------|-------------|
|  | 2019                         | 2018        |
| <b>Cash flows from operating activities:</b>   |                              |             |
| Net loss   | \$ (7,977)                   | \$ (28,515) |
| Less: Loss from discontinued operations  | 0                            | (3,354)     |
| Loss from continuing operations  | (7,977)                      | (25,161)    |
| Adjustments to reconcile net loss to net cash provided by operating activities:                    |                              |             |
| Depreciation and amortization  | 50,126                       | 47,948      |
| Operating right-of-use asset amortization  | 5,320                        | 0           |
| Stock-based compensation expense   | 11,658                       | 9,957       |
| Deferred taxes   | 6                            | 723         |
| Asset impairment charges   | 98                           | 0           |
| (Recovery) impairment of long-term investments   | (1,045)                      | 5,500       |
| Equity in net loss of unconsolidated investments   | 64                           | 61          |
| Loss on sale of businesses, net  | 0                            | 871         |
| Other income (losses), net   | 172                          | (941)       |
| Changes in operating assets and liabilities (net of businesses acquired):                          |                              |             |
| Accounts receivable and contract assets, net   | 32,307                       | 33,075      |
| Prepaid expenses and other assets  | 3,658                        | (6,501)     |
| Accounts payable   | 7,382                        | 4,707       |
| Accrued expenses   | (4,847)                      | 13,670      |
| Accrued compensation and benefits  | (39,525)                     | (18,610)    |
| Deferred revenue   | (17,107)                     | (13,894)    |
| Other liabilities  | 1,380                        | 2,910       |
| Operating leases   | (5,854)                      | 0           |
| Net cash provided by operating activities - continuing operations                                  | 35,816                       | 54,315      |
| Net cash (used in) provided by operating activities - discontinued operations                      | (30,000)                     | 3,993       |
| Net cash provided by operating activities  | 5,816                        | 58,308      |
| <b>Cash flows from investing activities:</b>   |                              |             |
| Capital expenditures   | (4,847)                      | (7,508)     |
| Capitalized software   | (28,600)                     | (26,168)    |
| Cash paid for business acquisitions, net of cash acquired  | 0                            | (107,212)   |
| Sales (purchases) of equity securities, other investments and related intangible assets, net       | 32                           | 0           |
| Other proceeds from investing activities   | 5                            | 37          |
| Net cash used in investing activities - continuing operations                                      | (33,410)                     | (140,851)   |
| Net cash used in investing activities - discontinued operations                                    | 0                            | (8,961)     |
| Net cash used in investing activities  | (33,410)                     | (149,812)   |
| <b>Cash flows from financing activities:</b>   |                              |             |
| Proceeds from sale or issuance of common stock   | 0                            | 212         |
| Taxes paid related to net share settlement of equity awards  | (5,327)                      | (8,496)     |
| Payments of lease obligations  | (55)                         | (255)       |
| Credit facility payments   | (5,000)                      | 0           |
| Credit facility borrowings, net of issuance costs  | 120,000                      | 145,843     |
| Repurchase of common stock   | (65,070)                     | (57,599)    |
| Payment of acquisition financing obligations   | 0                            | (3,226)     |
| Purchases of subsidiary shares owned by non-controlling interest                                   | (54,064)                     | 0           |
| Net cash (used in) provided by financing activities - continuing operations                        | (9,516)                      | 76,479      |
| Net cash used in financing activities - discontinued operations                                    | 0                            | (3,766)     |
| Net cash (used in) provided by financing activities  | (9,516)                      | 72,713      |
| Effect of exchange rate changes on cash and cash equivalents                                       | 163                          | 65          |
| Net decrease in cash and cash equivalents  | (36,947)                     | (18,726)    |
| Cash, cash equivalents and restricted cash, beginning of period                                    | 184,795                      | 162,498     |
| Cash, cash equivalents and restricted cash, end of period  | 147,848                      | 143,772     |
| Less: Cash and cash equivalents included in current assets attributable to discontinued operations | 0                            | (19,105)    |
| Cash, cash equivalents and restricted cash, end of period, excluding discontinued operations       | \$ 147,848                   | \$ 124,667  |

The accompanying notes are an integral part of these consolidated financial statements.



**ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(Unaudited)**

**1. Basis of Presentation and Significant Accounting Policies**

***Principles of Consolidation***

The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.

***Unaudited Interim Financial Information***

The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2019 and 2018 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three months ended March 31, 2019 are not necessarily indicative of the results to be expected for the full year ending December 31, 2019.

Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC’s rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 (our “Form 10-K”).

***Use of Estimates***

The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates.

***Change in Presentation***

During the first quarter of 2019, we changed our reportable segments from Clinical and Financial Solutions, Population Health and Unallocated to Provider, Veradigm and Unallocated. The business units reported within the historical segments have been reallocated into the new segments. Refer to Note 15 “Business Segments” for further discussion on the impact of the change.

***Significant Accounting Policies***

We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update No. 2016-02, “*Leases (Topic 842)*” (“ASU 2016-02”) on January 1, 2019 using the cumulative-effect adjustment transition method. This method requires us to recognize an adoption impact as a cumulative-effect adjustment to the January 1, 2019 retained earnings balance. Prior period balances were not adjusted upon adoption this standard. The standard requires that leased assets and corresponding lease liabilities be recognized within the consolidated balance sheets as right-to-use assets and operating or financing lease liabilities. Please refer to Note 3 “Leases” for further discussion on the impact of adoption.

***Recently Adopted Accounting Pronouncements***

In August 2017, the FASB issued Accounting Standards Update No. 2017-12, *Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities* (“ASU 2017-12”), which provides new accounting guidance to simplify and improve the reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. In addition to that main objective, the amendments in ASU 2017-12 make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. We adopted ASU 2017-12 on January 1, 2019 and the adoption did not have any effect on our consolidated financial statements.

In June 2018, the FASB issued Accounting Standards Update No. 2018-07, “*Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting*” (“ASU 2018-07”), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers. We adopted this standard on January 1, 2019 and the adoption did not have any effect on our consolidated financial statements.

## Accounting Pronouncements Not Yet Adopted

In August 2018, the FASB issued Accounting Standards Update No. 2018-13, "Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement" ("ASU 2018-13"), which eliminates, adds and modifies certain disclosure requirements for fair value measurements. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements ASU 2018-13 will be effective for all entities for interim and annual periods beginning after December 15, 2019, with early adoption permitted. We are currently evaluating the disclosure impact of this accounting guidance.

In June 2016, the FASB issued Accounting Standards Update No. 2016-13, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* ("ASU 2016-13"). The guidance in ASU 2016-13 replaces the incurred loss impairment methodology under current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. ASU 2016-13 is effective for annual periods beginning after December 15, 2019, and interim periods within those annual periods. Early adoption is permitted for fiscal years beginning after December 15, 2018. We are currently in the process of evaluating this new guidance, which we expect to have an impact on our consolidated financial statements and results of operations.

We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.

## 2. Revenue from Contracts with Customers

Our two primary revenue streams are (i) software delivery, support and maintenance and (ii) client services. Software delivery, support and maintenance revenue consists of all of our proprietary software sales (either under a perpetual or term license delivery model), subscription-based software sales, transaction-related revenue, the resale of hardware and third-party software and revenue from post-contract client support and maintenance services, which include telephone support services, maintaining and upgrading software and ongoing enhanced maintenance. Client services revenue consists of revenue from managed services solutions, such as private cloud hosting, outsourcing and revenue cycle management, as well as other client services and project-based revenue from implementation, training and consulting services. For some clients, we host the software applications licensed from us using our own or third-party servers. For other clients, we offer an outsourced service in which we assume partial to total responsibility for a healthcare organization's IT operations using our employees.

At March 31, 2019 and 2018, we had capitalized costs to obtain or fulfill a contract of \$22.7 million and \$27.4 million, respectively, in Prepaid and other current assets and \$32.0 million and \$37.3 million, respectively, in Other assets. During the three months ended March 31, 2019 and 2018, we recognized \$7.6 million and \$8.1 million, respectively, of amortization expense related to such capitalized costs, which is included in selling, general and administrative expenses within the consolidated statements of operations.

The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivables, contract assets and customer advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as current or long-term based on the timing of when we expect to recognize revenue.

The breakdown of revenue recognized related based on the origination of performance obligations and elected accounting expedients is presented in the table below:

| (In thousands)   | Three Months<br>Ended<br>March 31, 2019 |
|--|---|
| Revenue related to deferred revenue balance at beginning of period         | \$ 126,184                              |
| Revenue related to new performance obligations satisfied during the period | 248,221                                 |
| Revenue recognized under "right-to-invoice" expedient                      | 55,923                                  |
| Reimbursed travel expenses, shipping and other revenue                     | 1,721                                   |
| Total revenue  | \$ 432,049                              |

| (In thousands)   | Three Months<br>Ended<br>March 31, 2018 |                |
|--|---|----------------|
| Revenue related to deferred revenue balance at beginning of period         | \$                                      | 181,398        |
| Revenue related to new performance obligations satisfied during the period |   | 200,232        |
| Revenue recognized under "right-to-invoice" expedient                      |   | 49,403         |
| Reimbursed travel expenses, shipping and other revenue                     |   | 2,689          |
| Total revenue  | <u>\$</u>                               | <u>433,722</u> |

The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations (commonly referred to as "backlog") represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Total backlog equaled \$4.0 billion as of March 31, 2019, of which we expect to recognize approximately 38% over the next 12 months, and the remaining 62% thereafter.

#### Revenue Recognition

We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer's perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer.

The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment.

We disaggregate our revenue from contracts with customers based on the type of revenue and nature of revenue stream, as we believe those categories best depict how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments:

| (In thousands)        | Three Months Ended March 31 |                   |
|-----------------------|-----------------------------|-------------------|
|                       | 2019                        | 2018              |
| Revenue:              |                             |                   |
| Recurring revenue     | \$ 348,636                  | \$ 352,660        |
| Non-recurring revenue | 83,413                      | 81,062            |
| Total revenue         | <u>\$ 432,049</u>           | <u>\$ 433,722</u> |

| (In thousands)                             | Three Months Ended March 31, 2019 |                  |                 |                   |
|--|-----------------------------------|------------------|-----------------|-------------------|
|  | Provider                          | Veradigm         | Unallocated     | Total             |
| Software delivery, support and maintenance | \$ 237,355                        | \$ 34,042        | \$ 4,115        | \$ 275,512        |
| Client services                            | 155,252                           | 1,074            | 211             | 156,537           |
| Total revenue                              | <u>\$ 392,607</u>                 | <u>\$ 35,116</u> | <u>\$ 4,326</u> | <u>\$ 432,049</u> |

| (In thousands)                             | Three Months Ended March 31, 2018 |                  |               |                   |
|--|-----------------------------------|------------------|---------------|-------------------|
|  | Provider                          | Veradigm         | Unallocated   | Total             |
| Software delivery, support and maintenance | \$ 257,754                        | \$ 21,415        | \$ 1,384      | \$ 280,553        |
| Client services                            | 152,670                           | 1,392            | (893)         | 153,169           |
| Total revenue                              | <u>\$ 410,424</u>                 | <u>\$ 22,807</u> | <u>\$ 491</u> | <u>\$ 433,722</u> |

### 3. Leases

We adopted ASU 2016-02 on January 1, 2019 using the cumulative-effect adjustment transition method. The new guidance required the recognition of leased arrangements on the balance sheet as a right-of-use assets and liabilities pertaining to the rights and obligations created by the leased assets.

We determine whether an arrangement is a lease at inception. Assets leased under an operating lease arrangement are recorded in Right-of-use assets – operating leases and the associated lease liability is included in Current operating lease liabilities and Long-term operating lease liabilities within the consolidated balance sheets. Assets leased under finance lease arrangements are recorded within fixed assets and the associated lease liabilities are recorded within Accrued expenses and Other liabilities within the consolidated balance sheets.

Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate in conjunction with the market swap rate for the expected remaining lease term at commencement date for new leases, or as of January 1, 2019 for existing leases, in determining the present value of future lease payments. Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

We have elected the group of practical expedients under ASU 2016-02 to forego assessing upon adoption: (1) whether any expired contracts are or contain leases; (2) the lease classification for any existing or expired leases and (3) any indirect costs that would have qualified for capitalization for any existing leases. We have lease agreements with lease and non-lease components, which are generally accounted for separately except for real estate and vehicle leases, which we have elected to combine through a practical expedient under ASU 2016-02. Non-lease components for our leases typically comprise of executory costs, which under the practical expedient allows for all executory costs to be recorded as lease payments. Additionally, for certain equipment leases, we apply a portfolio approach to effectively record right-of-use assets and liabilities.

Our operating leases mainly include office leases and our finance leases include office and computer equipment leases. Our leases have remaining lease terms of approximately 1 year to 10 years, some of which include options to extend the leases for up to 5 years, which may include options to terminate the leases within 1 year. Total costs associated with leased assets are as follows:

| <b>(In thousands)</b>                              | <b>Three months ended<br/>March 31, 2019</b> |
|--|--|
| Operating lease cost <sup>(1)</sup>                | \$ 6,717                                     |
| Less: Sublease income                              | (802)  |
| <b>Total operating lease costs</b>                 | <b>5,915</b>                                 |
| Finance lease costs:                               |  |
| Amortization of right-of-use assets <sup>(2)</sup> | 51   |
| Interest on lease liability <sup>(3)</sup>         | 3  |
| <b>Total finance lease costs</b>                   | <b>\$ 54</b>                                 |

(1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statement of operations.

(2) Amortization of finance right-of-use assets is recognized on a straight-line basis and is included in in Selling, general and administrative expenses within the consolidated statement of operations.

(3) Interest on finance lease liabilities is recorded as Interest expense within the consolidated statement of operations.

Supplemental information for operating and finance leases is as follows:

| <b>(In thousands)</b>  | <b>Three months ended<br/>March 31, 2019</b> |
|--|--|
| <b>Cash paid for amounts included in the measurement of lease liabilities:</b> |  |
| Operating cash flows from operating leases                                     | \$ 7,287                                     |
| Operating cash flows from finance leases                                       | 3  |
| Financing cash flows from finance leases                                       | 37   |
| <b>Right-of-use assets obtained in exchange for lease obligations:</b>         |  |
| Operating leases   | \$ 124,811                                   |
| Finance leases   | 263  |

The balance sheet location and balances for operating and finance leases are as follows:

| <b>(In thousands, except lease term and discount rate)</b> | <b>March 31, 2019</b> |        |
|--|-----------------------|--------|
| <b>Operating leases:</b>                                   |                       |        |
| Right-of-use assets - operating leases                     | \$                    | 97,411 |
| Current operating lease liabilities                        | \$                    | 24,154 |
| Long-term operating lease liabilities                      | \$                    | 95,112 |
| <b>Finance leases:</b>                                     |                       |        |
| Fixed assets, gross  | \$                    | 524    |
| Accumulated depreciation                                   |                       | 286    |
| Fixed assets, net  | \$                    | 238    |
| Current finance lease liabilities <sup>(1)</sup>           | \$                    | 130    |
| Long-term finance lease liabilities <sup>(2)</sup>         | \$                    | 97     |
| <b>Weighted average remaining lease term (in years)</b>    |                       |        |
| Operating leases   |                       | 6      |
| Finance leases   |                       | 2      |
| <b>Weighted average discount rate</b>                      |                       |        |
| Operating leases   |                       | 4.6%   |
| Finance leases   |                       | 5.0%   |

(1) Current finance lease liabilities are included in Accrued expenses within the consolidated balance sheets.

(2) Long-term finance lease liabilities are included in Other liabilities within the consolidated balance sheets.

The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of March 31, 2019.

| <b>(in thousands)</b>              | <b>March 31, 2019</b>   |                       |
|------------------------------------|-------------------------|-----------------------|
|                                    | <b>Operating Leases</b> | <b>Finance Leases</b> |
| Remainder of 2019                  | \$ 22,128               | \$ 107                |
| 2020                               | 24,839                  | 85                    |
| 2021                               | 20,773                  | 40                    |
| 2022                               | 19,205                  | 6                     |
| 2023                               | 16,817                  | 0                     |
| Thereafter                         | 33,171                  | 0                     |
| Total lease liabilities            | 136,933                 | 238                   |
| Less: Amount representing interest | (17,667)                | (11)                  |
| Less: Short-term lease liabilities | (24,154)                | (130)                 |
| Total long-term lease liabilities  | \$ 95,112               | \$ 97                 |

#### 4. Business Combinations

On March 1, 2019, we acquired all of the outstanding minority interest in Pulse8, Inc., a healthcare analytics and technology company that provides business intelligence software solutions for health plans and at-risk providers to enable them to analyze their risk adjustment and quality management programs, for \$53.8 million (subject to adjustments for net working capital and a contingency holdback), plus up to a \$10.0 million earnout based upon revenue targets through 2019. We initially acquired a controlling stake in Pulse 8, Inc. on September 8, 2016. This transaction was treated as an equity transaction and the cash payment is reported as part of cash flow from financing activities in the consolidated statement of cash flows for the three months ended March 31, 2019.

## 5. Fair Value Measurements and Long-term Investments

Fair value measurements are based upon observable and unobservable inputs.

Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly.

Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:

| (In thousands)                        | Balance Sheet Classifications             | March 31, 2019 |               |                  |                  | December 31, 2018 |               |                  |                  |
|---------------------------------------|---|----------------|---------------|------------------|------------------|-------------------|---------------|------------------|------------------|
|                                       |   | Level 1        | Level 2       | Level 3          | Total            | Level 1           | Level 2       | Level 3          | Total            |
| Foreign exchange derivative assets    | Prepaid expenses and other current assets | \$ 0           | \$ 394        | \$ 0             | \$ 394           | \$ 0              | \$ 262        | \$ 0             | \$ 262           |
| 1.25% Call Option                     | Other assets                              | 0              | 0             | 3,030            | 3,030            | 0                 | 0             | 9,104            | 9,104            |
| <b>Total assets</b>                   |   | <u>\$ 0</u>    | <u>\$ 394</u> | <u>\$ 3,030</u>  | <u>\$ 3,424</u>  | <u>\$ 0</u>       | <u>\$ 262</u> | <u>\$ 9,104</u>  | <u>\$ 9,366</u>  |
| Contingent consideration - current    | Accrued expenses                          | 0              | 0             | 8,785            | 8,785            | 0                 | 0             | 10,528           | 10,528           |
| Contingent consideration - long-term  | Other liabilities                         | 0              | 0             | 22,074           | 22,074           | 0                 | 0             | 15,317           | 15,317           |
| 1.25% Embedded cash conversion option | Other liabilities                         | 0              | 0             | 3,525            | 3,525            | 0                 | 0             | 9,974            | 9,974            |
| <b>Total liabilities</b>              |   | <u>\$ 0</u>    | <u>\$ 0</u>   | <u>\$ 34,384</u> | <u>\$ 34,384</u> | <u>\$ 0</u>       | <u>\$ 0</u>   | <u>\$ 35,819</u> | <u>\$ 35,819</u> |

The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at March 31, 2019 are summarized as follows:

| (In thousands)               | Contingent Consideration | 1.25% Notes Call Spread Overlay |
|------------------------------|--------------------------|---------------------------------|
| Balance at December 31, 2018 | 25,845                   | (870)                           |
| Additions                    | 5,008                    | 0                               |
| Fair value adjustments       | 6                        | 375                             |
| Balance at March 31, 2019    | <u>\$ 30,859</u>         | <u>\$ (495)</u>                 |

### Long-term Investments

The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets:

| (In thousands, except for number of investees) | Number of Investees at March 31, 2019 | Original Cost    | Carrying Value at |                   |
|--|---------------------------------------|------------------|-------------------|-------------------|
|  |                                       |                  | March 31, 2019    | December 31, 2018 |
| Equity method investments (1)                  | 5                                     | \$ 7,407         | \$ 10,604         | \$ 10,667         |
| Cost method investments                        | 8                                     | 37,874           | 26,935            | 25,923            |
| <b>Total long-term equity investments</b>      | <u>13</u>                             | <u>\$ 45,281</u> | <u>\$ 37,539</u>  | <u>\$ 36,590</u>  |

(1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

As of March 31, 2019, it is not practicable to estimate the fair value of our non-marketable cost and equity method investments primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer's ability to meet its current obligations, the issuer's subsequent or planned raises of capital, and observable price changes in orderly transactions.

### Recovery and Impairment of Long-term Investments

During the three months ended March 31, 2019, we recovered \$1.0 million from a third-party cost-method investment that we had previously impaired. Each quarter, management performs an assessment of each of our investments on an individual basis to determine if there have been any declines in fair value. As a result of this review, we recognized a non-cash impairment charge during the three months ended March 31, 2018 of \$5.5 million related to one of our cost-method equity investments and a related note receivable, which had cost bases of \$4.9 million and \$2.6 million, respectively, prior to the impairment.

### Long-term Financial Liabilities

Our long-term financial liabilities include amounts outstanding under our senior secured credit facility (as defined in Note 9, "Debt"), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the "1.25% Notes") approximates fair value as of March 31, 2019, since the effective interest rate on the 1.25% Notes approximates current market rates. Refer to Note 9, "Debt," for further information regarding our long-term financial liabilities.

## 6. Stockholders' Equity

### Stock-based Compensation Expense

Stock-based compensation expense recognized during the three months ended March 31, 2019 and 2018 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three months ended March 31, 2019 and 2018.

| (In thousands)                               | Three Months Ended<br>March 31, |                  |
|--|---------------------------------|------------------|
|  | 2019                            | 2018             |
| Cost of revenue:                             |                                 |                  |
| Software delivery, support and maintenance   | \$ 513                          | \$ 596           |
| Client services                              | 1,093                           | 1,408            |
| Total cost of revenue                        | 1,606                           | 2,004            |
| Selling, general and administrative expenses | 8,325                           | 6,132            |
| Research and development                     | 2,877                           | 2,807            |
| Total stock-based compensation expense       | <u>\$ 12,808</u>                | <u>\$ 10,943</u> |

### Allscripts Long-Term Incentive Plan

We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved.

The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three months ended March 31, 2019 and 2018.

We granted stock-based awards as follows:

| (In thousands, except per share amounts)                     | Three Months Ended<br>March 31, 2019 |  |
|--|--------------------------------------|--|
|  | Shares                               | Weighted-Average<br>Grant Date<br>Fair Value |
| Service-based restricted stock units                         | 1,040                                | \$ 10.72                                     |
| Market-based restricted stock units with a service condition | 700                                  | \$ 11.74                                     |
|  | <u>1,740</u>                         | <u>\$ 11.13</u>                              |

During the three months ended March 31, 2019 and the year ended December 31, 2018, 1.1 million and 1.6 million shares of common stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards.

### Net Share-settlements

Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the three months ended March 31, 2019 and 2018 were net-share settled such that we withheld shares with fair value equivalent to the employees' minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the three months ended March 31, 2019 and 2018 were 508 thousand and 609 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting.

### ***Stock Repurchases***

On November 17, 2016, we announced that our Board approved a stock purchase program (the "2016 Program") under which we may repurchase up to \$200 million of our common stock through December 31, 2019. On August 2, 2018, we announced that our Board approved a new stock purchase program (the "2018 Program") under which we may repurchase up to \$250 million of our common stock through December 31, 2020, replacing the 2016 Program. We repurchased 6.1 million shares of our common stock under the 2018 Program for a total of \$64.9 million during the three months ended March 31, 2019. The approximate dollar value of shares that may yet be purchased under the 2018 Program is \$148.1 million as of March 31, 2019. We repurchased 4.1 million shares of our common stock under the 2016 Program for a total of \$57.6 million during the three months ended March 31, 2018. Any future stock repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

### **7. Earnings (Loss) Per Share**

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted-average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method.



The calculations of earnings (loss) per share are as follows:

| (In thousands, except per share amounts)  | Three Months Ended<br>March 31, |             |
|---|---------------------------------|-------------|
|   | 2019                            | 2018        |
| <b>Basic earnings (loss) per Common Share:</b>  |                                 |             |
| Loss from continuing operations, net of tax   | \$ (7,977)                      | \$ (25,161) |
| Net loss attributable to non-controlling interests  | 424                             | 790         |
| Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders          | \$ (7,553)                      | \$ (24,371) |
| Loss from discontinued operations, net of tax   | \$ 0                            | \$ (3,354)  |
| Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations | 0                               | (12,149)    |
| Net loss from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders        | 0                               | (15,503)    |
| Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders                                     | \$ (7,553)                      | \$ (39,874) |
| Weighted-average common shares outstanding  | 169,957                         | 179,882     |
| Basic earnings (loss) from continuing operations per Common Share   | \$ (0.04)                       | \$ (0.14)   |
| Basic income from discontinued operations per Common Share  | 0.00                            | (0.08)      |
| Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share                    | \$ (0.04)                       | \$ (0.22)   |
| <b>Diluted earnings (loss) per Common Share:</b>  |                                 |             |
| Loss from continuing operations, net of tax   | \$ (7,977)                      | \$ (25,161) |
| Net loss attributable to non-controlling interests  | 424                             | 790         |
| Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders          | \$ (7,553)                      | \$ (24,371) |
| Loss from discontinued operations, net of tax   | \$ 0                            | \$ (3,354)  |
| Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations | 0                               | (12,149)    |
| Net loss from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders        | 0                               | (15,503)    |
| Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders                                     | \$ (7,553)                      | \$ (39,874) |
| Weighted-average common shares outstanding  | 169,957                         | 179,882     |
| Plus: Dilutive effect of stock options, restricted stock unit awards and warrants                               | 0                               | 0           |
| Weighted-average common shares outstanding assuming dilution  | 169,957                         | 179,882     |
| Diluted earnings (loss) from continuing operations per Common Share   | \$ (0.04)                       | \$ (0.14)   |
| Diluted income from discontinued operations per Common Share  | 0.00                            | (0.08)      |
| Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share                    | \$ (0.04)                       | \$ (0.22)   |

Due to the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the three months ended March 31, 2019 and 2018, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for those periods, since the inclusion of any stock equivalents would be anti-dilutive.

The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:

| (In thousands)   | Three Months Ended<br>March 31, |        |
|--|---------------------------------|--------|
|  | 2019                            | 2018   |
| Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation | 26,738                          | 23,208 |

## 8. Goodwill and Intangible Assets

Goodwill and intangible assets consist of the following:

| (In thousands)                           | March 31, 2019        |                          |                        | December 31, 2018     |                          |                        |
|--|-----------------------|--------------------------|------------------------|-----------------------|--------------------------|------------------------|
|  | Gross Carrying Amount | Accumulated Amortization | Intangible Assets, Net | Gross Carrying Amount | Accumulated Amortization | Intangible Assets, Net |
| Intangibles subject to amortization:     |                       |                          |                        |                       |                          |                        |
| Proprietary technology                   | \$ 537,952            | \$ (410,154)             | \$ 127,798             | \$ 537,834            | \$ (401,093)             | \$ 136,741             |
| Customer contracts and relationships     | 704,965               | (469,326)                | 235,639                | 704,808               | (462,468)                | 242,340                |
| Total                                    | <u>\$ 1,242,917</u>   | <u>\$ (879,480)</u>      | <u>\$ 363,437</u>      | <u>\$ 1,242,642</u>   | <u>\$ (863,561)</u>      | <u>\$ 379,081</u>      |
| Intangibles not subject to amortization: |                       |                          |                        |                       |                          |                        |
| Registered trademarks                    |                       |                          | \$ 52,000              |                       |                          | \$ 52,000              |
| Goodwill                                 |                       |                          | 1,373,996              |                       |                          | 1,373,744              |
| Total                                    |                       |                          | <u>\$ 1,425,996</u>    |                       |                          | <u>\$ 1,425,744</u>    |

Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2019 were as follows:

| (In thousands)                  | Provider            | Veradigm          | Total               |
|---------------------------------|---------------------|-------------------|---------------------|
| Balance as of December 31, 2018 | \$ 1,254,284        | \$ 119,460        | \$ 1,373,744        |
| Foreign exchange translation    | 252                 | 0                 | 252                 |
| Balance as of March 31, 2019    | <u>\$ 1,254,536</u> | <u>\$ 119,460</u> | <u>\$ 1,373,996</u> |

There are \$13.5 million in accumulated impairment losses associated with our goodwill as of March 31, 2019 and December 31, 2018.

## 9. Debt

Debt outstanding, excluding lease obligations, consists of the following:

| (In thousands)                                | March 31, 2019    |  |                     | December 31, 2018 |  |                     |
|---|-------------------|--|---------------------|-------------------|--|---------------------|
|   | Principal Balance | Unamortized Discount and Debt Issuance Costs | Net Carrying Amount | Principal Balance | Unamortized Discount and Debt Issuance Costs | Net Carrying Amount |
| 1.25% Cash Convertible Senior Notes           | \$ 345,000        | \$ 18,534                                    | \$ 326,466          | \$ 345,000        | \$ 22,112                                    | \$ 322,888          |
| Senior Secured Credit Facility                | 465,000           | 5,660  | 459,340             | 350,000           | 6,038  | 343,962             |
| Other debt                                    | 952               | 0  | 952                 | 748               | 0  | 748                 |
| Total debt                                    | <u>\$ 810,952</u> | <u>\$ 24,194</u>                             | <u>\$ 786,758</u>   | <u>\$ 695,748</u> | <u>\$ 28,150</u>                             | <u>\$ 667,598</u>   |
| Less: Debt payable within one year            | 20,952            | 434  | 20,518              | 20,538            | 479  | 20,059              |
| Total long-term debt, less current maturities | <u>\$ 790,000</u> | <u>\$ 23,760</u>                             | <u>\$ 766,240</u>   | <u>\$ 675,210</u> | <u>\$ 27,671</u>                             | <u>\$ 647,539</u>   |

Interest expense consists of the following:

| (In thousands)                                    | Three Months Ended March 31, |                  |
|---|------------------------------|------------------|
|   | 2019                         | 2018             |
| Interest expense                                  | \$ 6,229                     | \$ 7,938         |
| Amortization of discounts and debt issuance costs | 3,955                        | 3,756            |
| Total interest expense                            | <u>\$ 10,184</u>             | <u>\$ 11,694</u> |

Interest expense related to the 1.25% Cash Convertible Senior Notes (the "1.25% Notes"), included in the table above, consists of the following:

| (In thousands)                                    | Three Months Ended March 31, |                 |
|---|------------------------------|-----------------|
|   | 2019                         | 2018            |
| Coupon interest at 1.25%                          | 1,078                        | \$ 1,078        |
| Amortization of discounts and debt issuance costs | 3,577                        | 3,407           |
| Total interest expense related to the 1.25% Notes | <u>\$ 4,655</u>              | <u>\$ 4,485</u> |

### Allscripts Senior Secured Credit Facility

On February 15, 2018, Allscripts and Healthcare LLC entered into a Second Amended and Restated Credit Agreement (the "Second Amended Credit Agreement"), with JPMorgan Chase Bank, N.A., as administrative agent. The Second Amended Credit Agreement provides for a \$400 million senior secured term loan (the "Term Loan") and a \$900 million senior secured revolving facility (the "Revolving Facility"), each with a five-year term. The Term Loan is repayable in quarterly installments, which began on June 30, 2018. A total of up to \$50 million of the Revolving Facility is available for the issuance of letters of credit, up to \$10 million of the Revolving Facility is available for swingline loans, and up to \$100 million of the Revolving Facility could be borrowed under certain foreign currencies.

As of March 31, 2019, \$345 million under the Term Loan, \$120 million under the Revolving Facility, and \$0.8 million in letters of credit were outstanding under the Second Amended Credit Agreement.

As of March 31, 2019, the interest rate on the borrowings under the Second Amended Credit Agreement was LIBOR plus 2.00%, which totaled 4.50%. We were in compliance with all covenants under the Second Amended Credit Agreement as of March 31, 2019.

As of March 31, 2019, we had \$899.2 million available, net of outstanding letters of credit, under our Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of our Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings.

### 1.25% Cash Convertible Senior Notes

As of March 31, 2019, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes' principal amount.

The following table summarizes future debt payment obligations as of March 31, 2019:

| (In thousands)  | Total             | Remainder<br>of 2019 | 2020              | 2021             | 2022             | 2023              | Thereafter  |
|---|-------------------|----------------------|-------------------|------------------|------------------|-------------------|-------------|
| 1.25% Cash Convertible Senior<br>Notes <sup>(1)</sup> | \$ 345,000        | \$ 0                 | \$ 345,000        | \$ 0             | \$ 0             | \$ 0              | \$ 0        |
| Term Loan   | 345,000           | 15,000               | 27,500            | 30,000           | 37,500           | 235,000           | 0           |
| Revolving Facility <sup>(2)</sup>                     | 120,000           | 0                    | 0                 | 0                | 0                | 120,000           | 0           |
| Other debt  | 952               | 952                  | 0                 | 0                | 0                | 0                 | 0           |
| Total debt  | <u>\$ 810,952</u> | <u>\$ 15,952</u>     | <u>\$ 372,500</u> | <u>\$ 30,000</u> | <u>\$ 37,500</u> | <u>\$ 355,000</u> | <u>\$ 0</u> |

(1) Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

(2) Assumes no additional borrowings after March 31, 2019, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

### 10. Income Taxes

We account for income taxes under FASB Accounting Standards Codification 740, *Income Taxes* ("ASC 740"). We calculate the quarterly tax provision consistent with the guidance provided by ASC 740-270, whereby we forecast the estimated annual effective tax rate and then apply that rate to the year-to-date pre-tax book (loss) income. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective rate, including factors such as the valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, or changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. There is no tax benefit recognized on certain of the net operating losses incurred due to insufficient evidence supporting the Company's ability to use these losses in the future. The effective tax rates were as follows:

| (In thousands)                                      | Three Months Ended<br>March 31, |             |
|---|---------------------------------|-------------|
|   | 2019                            | 2018        |
| Loss from continuing operations before income taxes | \$ (6,045)                      | \$ (24,862) |
| Income tax provision                                | \$ (1,932)                      | \$ (299)    |
| Effective tax rate                                  | (32.0%)                         | (1.2%)      |

Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to permanent differences, income attributable to foreign jurisdictions taxed at different rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three months ended March 31, 2019, compared with the prior year comparable period, differs primarily due to higher tax shortfalls associated with stock-based compensation reflected in the provision for the three months ended March 31, 2019 and valuation allowance of \$10.7 million recorded in the three months ended March 31, 2018.

In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). During the three months ended March 31, 2019, we recorded immaterial impacts for valuation allowances.

Our unrecognized income tax benefits were \$20.8 million and \$19.8 million as of March 31, 2019 and December 31, 2018, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted in light of changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations, and changes in tax law.

## 11. Derivative Financial Instruments

The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates:

| (In thousands)                               | March 31, 2019                            |                 |                        |                 |
|--|---|-----------------|------------------------|-----------------|
|  | Asset Derivatives                         |                 | Liability Derivatives  |                 |
|  | Balance Sheet Location                    | Fair Value      | Balance Sheet Location | Fair Value      |
| Derivatives qualifying as cash flow hedges:  |   |                 |                        |                 |
| Foreign exchange contracts                   | Prepaid expenses and other current assets | \$ 394          | Accrued expenses       | \$ 0            |
| Derivatives not subject to hedge accounting: |   |                 |                        |                 |
| 1.25% Call Option                            | Other assets                              | 3,030           | N/A                    |                 |
| 1.25% Embedded cash conversion option        | N/A                                       |                 | Other liabilities      | 3,525           |
| Total derivatives                            |   | <u>\$ 3,424</u> |                        | <u>\$ 3,525</u> |

| (In thousands)                               | December 31, 2018                         |                 |                        |                 |
|--|---|-----------------|------------------------|-----------------|
|  | Asset Derivatives                         |                 | Liability Derivatives  |                 |
|  | Balance Sheet Location                    | Fair Value      | Balance Sheet Location | Fair Value      |
| Derivatives qualifying as cash flow hedges:  |   |                 |                        |                 |
| Foreign exchange contracts                   | Prepaid expenses and other current assets | \$ 262          | Accrued expenses       | \$ 0            |
| Derivatives not subject to hedge accounting: |   |                 |                        |                 |
| 1.25% Call Option                            | Other assets                              | 9,104           | N/A                    |                 |
| 1.25% Embedded cash conversion option        | N/A                                       |                 | Other liabilities      | 9,974           |
| Total derivatives                            |   | <u>\$ 9,366</u> |                        | <u>\$ 9,974</u> |

N/A – We define “N/A” as disclosure not being applicable

### Foreign Exchange Contracts

We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a decreasing percentage of forecasted monthly INR expenses over time. As of March 31, 2019, there were 9 forward contracts outstanding that were staggered to mature monthly starting in April 2019 and ending in December 2019. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond December 2019. As of March 31, 2019, the notional amount for each of the outstanding forward contracts was 160 million INR, or the equivalent of \$2.3 million, based on the exchange rate between the United States dollar and the INR in effect as of March 31, 2019. These amounts also approximate the forecasted future INR expenses we target to hedge in any one month in the future. As of March 31, 2019, we estimate that \$0.4 million of net unrealized derivative gains included in AOCI will be reclassified into income within the next twelve months.

The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss:

| (In thousands)             | Amount of Gain (Loss) Recognized in OCI |     | Location of Gain (Loss) Reclassified from AOCI into Income | Amount of Gain (Loss) Reclassified from AOCI into Income |   |
|----------------------------|---|-----|--|--|---|
|                            | Three Months Ended                      |     |  | Three Months Ended                                       |   |
|                            | March 31, 2019                          |     |  | March 31, 2019   |   |
| Foreign exchange contracts | \$                                      | 151 | Cost of Revenue  | \$   | 7 |
|                            |   |     | Selling, general and administrative expenses               |  | 5 |
|                            |   |     | Research and development                                   | \$   | 7 |

| (In thousands)             | Amount of Gain (Loss) Recognized<br>in OCI | Location of Gain (Loss) Reclassified<br>from AOCI into Income | Amount of Gain (Loss) Reclassified<br>from AOCI into Income |
|----------------------------|--|---|---|
|                            | Three Months<br>Ended<br>March 31, 2018    |   | Three Months<br>Ended<br>March 31, 2018                     |
| Foreign exchange contracts | \$ (78)                                    | Cost of Revenue   | \$ 189  |
|                            |  | Selling, general and administrative expenses                  | 144   |
|                            |  | Research and development                                      | \$ 222  |

### **1.25% Call Option**

In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes.

The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment (due to the cash settlement features) until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy.

The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in Other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal.

### **1.25% Notes Embedded Cash Conversion Option**

The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in Other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was \$82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy.

The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations:

| (In thousands)                         | Three Months Ended<br>March 31, |             |
|--|---------------------------------|-------------|
|  | 2019                            | 2018        |
| 1.25% Call Option                      | \$ (6,074)                      | \$ (21,168) |
| 1.25% Embedded cash conversion option  | 6,449                           | 21,331      |
| Net loss included in other income, net | \$ 375                          | \$ 163      |

## 12. Other Comprehensive Income

### Accumulated Other Comprehensive Loss

Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest.

| (In thousands)  | Foreign Currency<br>Translation<br>Adjustments | Unrealized Net Gains on<br>Foreign Exchange<br>Contracts | Total             |
|---|--|--|-------------------|
| Balance as of December 31, 2018 <sup>(1)</sup>                            | \$ (5,584)                                     | \$ 195   | \$ (5,389)        |
| Other comprehensive income (loss) before reclassifications                | 695  | 111  | 806               |
| Net (gains) losses reclassified from accumulated other comprehensive loss | 0  | (14)   | (14)              |
| Net other comprehensive loss  | 695  | 97   | 792               |
| Balance as of March 31, 2019 <sup>(2)</sup>                               | <u>\$ (4,889)</u>                              | <u>\$ 292</u>  | <u>\$ (4,597)</u> |

(1) Net of taxes of \$68 thousand for unrealized net gains on foreign exchange contract derivatives and \$149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income.

(2) Net of taxes of \$102 thousand for unrealized net losses on foreign exchange contract derivatives.

| (In thousands)  | Foreign Currency<br>Translation Adjustments | Unrealized Net Gains on<br>Foreign Exchange<br>Contracts | Total             |
|---|---|--|-------------------|
| Balance as of December 31, 2017 <sup>(1)</sup>                            | \$ (2,676)                                  | \$ 691   | \$ (1,985)        |
| Other comprehensive income (loss) before reclassifications                | 123   | (58)   | 65                |
| Net (gains) losses reclassified from accumulated other comprehensive loss | 0   | (261)  | (261)             |
| Net other comprehensive income  | 123   | (319)  | (196)             |
| Balance as of March 31, 2018 <sup>(2)</sup>                               | <u>\$ (2,553)</u>                           | <u>\$ 372</u>  | <u>\$ (2,181)</u> |

(1) Net of taxes of \$445 thousand for unrealized net gains on foreign exchange contract derivatives.

(2) Net of taxes of \$131 thousand for unrealized net losses on foreign exchange contract derivatives and \$149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income.

### Income Tax Effects Related to Components of Other Comprehensive Income (Loss)

The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) ("OCI"):

| (In thousands)  | Three Months Ended March 31, |                |               |                      |               |                 |
|---|------------------------------|----------------|---------------|----------------------|---------------|-----------------|
|   | 2019                         |                |               | 2018                 |               |                 |
|   | Before-Tax<br>Amount         | Tax Effect     | Net Amount    | Before-Tax<br>Amount | Tax Effect    | Net Amount      |
| Foreign currency translation adjustments                              | \$ 695                       | \$ 0           | \$ 695        | \$ 123               | \$ 0          | \$ 123          |
| Foreign exchange contracts:   |                              |                |               |                      |               |                 |
| Net (losses) gains arising during the period                          | 151                          | (40)           | 111           | (78)                 | 20            | (58)            |
| Net losses (gains) reclassified into income <sup>(1)</sup>            | (19)                         | 5              | (14)          | (555)                | 294           | (261)           |
| Net change in unrealized (losses) gains on foreign exchange contracts | 132                          | (35)           | 97            | (633)                | 314           | (319)           |
| Net (loss) gain on cash flow hedges                                   | 132                          | (35)           | 97            | (633)                | 314           | (319)           |
| Other comprehensive (loss) income                                     | <u>\$ 827</u>                | <u>\$ (35)</u> | <u>\$ 792</u> | <u>\$ (510)</u>      | <u>\$ 314</u> | <u>\$ (196)</u> |

(1) Tax effects for the three months ended March 31, 2018 include \$149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income at December 31, 2017.

## 13. Contingencies

In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves in these matters.

No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made.

The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these legal proceedings were resolved against or settled by us in a reporting period for amounts in excess of our management's expectations, our consolidated financial statements for that and subsequent reporting periods could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results.

On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in the U.S. District Court for the Northern District of Illinois against us. The complaint alleges that, on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients' express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the "TCPA"). The plaintiff sought \$500 for each alleged violation of the TCPA, treble damages if the Court finds the violations to be willful, knowing or intentional, and injunctive and other relief. Allscripts answered the complaint denying all material allegations and asserting a number of affirmative defenses, as well as counterclaims for breach of a license agreement. On March 31, 2016, plaintiff filed its motion for class certification. On May 31, 2016, we filed our opposition to plaintiff's motion for class certification, and simultaneously moved for summary judgment on all of plaintiff's claims. On June 2, 2017, an order was entered denying class certification and, accordingly, the case will not proceed on a class-wide basis.

The EIS Business acquired from McKesson on October 2, 2017 is subject to a May 2017 civil investigative demand ("CID") from the U.S. Attorney's Office for the Eastern District of New York. The CID requests documents and information related to the certification McKesson obtained for Horizon Clinicals in connection with the U.S. Department of Health and Human Services' Electronic Health Record Incentive Program. In August 2018, McKesson received an additional CID seeking similar information for Paragon. McKesson has agreed, with respect to the CIDs, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition.

Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney's Office for the District of Vermont pursuant to a CID. Between April 2018 and January 2019, Practice Fusion received five additional requests for documents and information through another CID and Health Insurance Portability and Accountability Act ("HIPAA") subpoenas. In March 2019, Practice Fusion received a grand jury subpoena in connection with a related criminal investigation. The document and information requests received by Practice Fusion relate to both the certification Practice Fusion obtained in connection with the U.S. Department of Health and Human Services' Electronic Health Record Incentive Program and Practice Fusion's compliance with the Anti-Kickback Statute and HIPAA as it relates to certain business practices engaged in by Practice Fusion. Practice Fusion continues to produce documents and information in response to these various requests.

On January 25, 2018, a complaint was filed in *Surfside Non-Surgical Orthopedics, P.A. v. Allscripts Healthcare Solutions, Inc.*, No. 1:18-cv-00566, in the Northern District of Illinois. This is a purported class action lawsuit related to a January 18, 2018 ransomware attack, and alleges the following counts: (1) negligence, gross negligence and negligence per se; (2) breach of contract; (3) unjust enrichment; (4) violation of the Illinois Consumer Fraud Act; and (5) violation of the Illinois Deceptive Trade Practices Act. Plaintiff seeks to represent a class of customers seeking damages from Allscripts. Allscripts has moved to dismiss the plaintiff's complaint.



## 14. Discontinued Operations

### *Netsmart*

On December 31, 2018, we sold all of the Class A Common Units of Netsmart LLC, a Delaware limited liability company (“Netsmart”) held by the Company. Prior to the sale, Netsmart comprised a separate reportable segment, which due to its significance to our historical consolidated financial statements and results of operations, is reported as a discontinued operation as a result of the sale.

The following table summarizes Netsmart’s major income and expense line items as reported in the consolidated statements of operations for the three months ended March 31, 2018:

| <b>(In thousands)</b>   | <b>Three Months Ended<br/>March 31, 2018</b> |
|---|--|
| <b>Major income and expense line items related to Netsmart:</b>               |  |
| Revenue:  |  |
| Software delivery, support and maintenance                                    | \$ 49,213                                    |
| Client services   | 30,991                                       |
| Total revenue   | 80,204                                       |
| Cost of revenue:  |  |
| Software delivery, support and maintenance                                    | 14,367                                       |
| Client services   | 21,713                                       |
| Amortization of software development and acquisition related assets           | 7,814  |
| Total cost of revenue   | 43,894                                       |
| Gross profit  | 36,310                                       |
| Selling, general and administrative expenses                                  | 23,133                                       |
| Research and development  | 5,187  |
| Amortization of intangible and acquisition-related assets                     | 5,609  |
| Income from discontinued operations for the Netsmart sale before income taxes | 2,381  |
| Interest expense  | (13,351)                                     |
| Other loss  | (12)   |
| Income tax benefit  | 3,213  |
| Loss from discontinued operations, net of tax for Netsmart                    | \$ (7,769)                                   |

### *Horizon Clinicals and Series2000 Revenue Cycle*

Two of the product offerings (Horizon Clinicals and Series2000 Revenue Cycle) acquired with the Enterprise Information Solutions (the “EIS Business”) business combination were sunset after March 31, 2018. The decision to discontinue maintaining and supporting these solutions was made prior to our acquisition of the EIS Business and, therefore, are presented below as discontinued operations. Until the end of the first quarter of 2018, we were involved in ongoing maintenance and support for these solutions until customers have transitioned to other platforms. No disposal gains or losses were recognized during the 2018 fiscal year related to these discontinued operations. We had \$0.9 million of accrued expenses associated with the Horizon Clinicals and Series2000 Revenue Cycle businesses on the consolidated balance sheets as of December 31, 2018.

The following table summarizes the major classes of line items constituting income (loss) of the discontinued operations specifically with the sunset businesses of Horizon Clinicals and Series2000 Revenue Cycle, as reported in the consolidated statements of operations for the three months ended March 31, 2018:

| (In thousands)   | Three Months Ended<br>March 31, 2018 |         |
|--|--------------------------------------|---------|
| Major classes of line items constituting pretax profit (loss) of discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle: |                                      |         |
| Revenue:   |                                      |         |
| Software delivery, support and maintenance   | \$                                   | 9,804   |
| Client services  |                                      | 492     |
| Total revenue  |                                      | 10,296  |
| Cost of revenue:   |                                      |         |
| Software delivery, support and maintenance   |                                      | 2,463   |
| Client services  |                                      | 743     |
| Total cost of revenue  |                                      | 3,206   |
| Gross profit   |                                      | 7,090   |
| Research and development   |                                      | 1,124   |
| Income from discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle before income taxes                                   |                                      | 5,966   |
| Income tax provision   |                                      | (1,551) |
| Income from discontinued operations, net of tax for Horizon Clinicals and Series2000 Revenue Cycle   | \$                                   | 4,415   |

## 15. Business Segments

We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management.

During the three months ended March 31, 2019, we realigned our reporting structure as a result of the divestiture of our investment in Netsmart on December 31, 2018, the evolution of the healthcare IT industry and our increased focus on the payer and life sciences market. As a result, we changed the presentation of our reportable segments to Provider and Veradigm. The new Provider segment is comprised of our core integrated clinical software applications, financial management and patient engagement solutions targeted at clients across the entire continuum of care. The new Veradigm segment primarily focuses on the payer and life sciences market. These changes to our reportable segments had no impact on operating segments. The segment disclosures below for the three months ended March 31, 2018, have been revised to conform to the current year presentation.

As of March 31, 2019, we had eight operating segments, which are aggregated into two reportable segments. The Provider reportable segment includes the Hospitals and Health Systems, Ambulatory, CarePort, FollowMyHealth®, EPSi™, EIS-Classics and 2bPrecise strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from the sale of integrated clinical software applications, financial management and patient engagement solutions, which primarily include EHR-related software, connectivity and coordinated care solutions, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training and electronic claims administration services. The Veradigm reportable segment is comprised of the Veradigm business unit, which represents a separate operating segment. This reportable segment provides data-driven clinical insights with actionable tools for clinical workflow, research, analytics and media. Its solutions, targeted at key healthcare stakeholders, help improve the quality, efficiency and value of healthcare delivery.

Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and income from operations as measures of performance and to make decisions about the allocation of resources. In determining these performance measures, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenue acquired in a business combination. We also exclude the amortization of intangible assets, stock-based compensation expense, expenses not reflective of our core business and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Expenses not reflective of our core business relate to certain severance, product consolidation, legal, consulting and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes (i) corporate general and administrative expenses (including marketing expenses) and certain research and development expenses related to common solutions and resources that benefit all of our business units, all of which are centrally managed, and (ii) revenue and the associated cost from the resale of certain ancillary products, primarily hardware. We do not track our assets by segment.

| (In thousands)                             | Three Months Ended<br>March 31, |                   |
|--|---------------------------------|-------------------|
|  | 2019                            | 2018              |
| <b>Revenue:</b>                            |                                 |                   |
| Provider                                   | \$ 392,607                      | \$ 410,424        |
| Veradigm                                   | 35,116                          | 22,807            |
| Unallocated Amounts                        | 4,326                           | 491               |
| <b>Total revenue</b>                       | <b>\$ 432,049</b>               | <b>\$ 433,722</b> |
| <b>Gross Profit:</b>                       |                                 |                   |
| Provider                                   | \$ 165,818                      | \$ 185,729        |
| Veradigm                                   | 22,434                          | 15,130            |
| Unallocated Amounts                        | (14,157)                        | (16,194)          |
| <b>Total gross profit</b>                  | <b>\$ 174,095</b>               | <b>\$ 184,665</b> |
| <b>Income (loss) from operations:</b>      |                                 |                   |
| Provider                                   | \$ 100,274                      | \$ 107,140        |
| Veradigm                                   | 8,319                           | 5,032             |
| Unallocated Amounts                        | (105,948)                       | (118,873)         |
| <b>Total income (loss) from operations</b> | <b>\$ 2,645</b>                 | <b>\$ (6,701)</b> |

## 16. Supplemental Disclosures

### Supplemental Consolidated Statements of Cash Flows Information

The majority of the restricted cash balance as of March 31, 2019 and 2018 represents the remaining balance of the escrow account established as part of the acquisition of Netsmart in 2016 to be used by Netsmart to facilitate the integration of Allscripts’ former Homecare™ business.

| (In thousands)   | March 31,         |                   |
|--|-------------------|-------------------|
|  | 2019              | 2018              |
| <b>Reconciliation of cash, cash equivalents and restricted cash:</b> |                   |                   |
| Cash and cash equivalents  | \$ 137,167        | \$ 111,999        |
| Restricted cash  | 10,681            | 12,668            |
| <b>Total cash, cash equivalents and restricted cash</b>              | <b>\$ 147,848</b> | <b>\$ 124,667</b> |

| (In thousands)   | Three Months Ended<br>March 31, |           |
|--|---------------------------------|-----------|
|  | 2019                            | 2018      |
| <b>Supplemental non-cash information:</b>  |                                 |           |
| Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operation | \$ 0                            | \$ 12,149 |
| Contribution of assets in exchange for equity interest   | \$ 0                            | \$ 4,000  |

## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*This "Management's Discussion and Analysis of Financial Condition and Results of Operations" section and other sections of this Quarterly Report on Form 10-Q ("Form 10-Q") contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical fact or pattern. Forward-looking statements can also be identified by the use of words such as "future," "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "will," "would," "could," "can," "may," and similar terms. Forward-looking statements are not guarantees of future performance. Actual results could differ significantly from those set forth in the forward-looking statements and reported results should not be considered an indication of future performance. Certain factors that could cause our actual results to differ materially from those described in the forward-looking statements include, but are not limited to, those discussed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018 (our "Form 10-K") under the heading "Risk Factors" and elsewhere. Certain factors that could cause Allscripts actual results to differ materially from those described in the forward-looking statements include, but are not limited to: the expected financial contribution of businesses acquired by us, including the EIS business, the NantHealth provider/patient solutions business, Practice Fusion and HealthGrid; the successful integration of businesses recently acquired by us; the anticipated and unanticipated expenses and liabilities related to the EIS business, the NantHealth provider/patient solutions business, Practice Fusion and HealthGrid, including with respect to the investigations by the U.S. Attorney's Office involving our EIS Business and Practice Fusion; security breaches resulting in unauthorized access to our or our clients' computer systems or data, including denial-of-services, ransomware or other Internet-based attacks; Allscripts failure to compete successfully; consolidation in Allscripts industry; current and future laws, regulations and industry initiatives; increased government involvement in Allscripts industry; the failure of markets in which Allscripts operates to develop as quickly as expected; Allscripts or its customers' failure to see the benefits of government programs; changes in interoperability or other regulatory standards; the effects of the realignment of Allscripts sales, services and support organizations; market acceptance of Allscripts products and services; the unpredictability of the sales and implementation cycles for Allscripts products and services; Allscripts ability to manage future growth; Allscripts ability to introduce new products and services; Allscripts ability to establish and maintain strategic relationships; risks related to the acquisition of new businesses or technologies; the performance of Allscripts products; Allscripts ability to protect its intellectual property rights; the outcome of legal proceedings involving Allscripts; Allscripts ability to hire, retain and motivate key personnel; performance by Allscripts content and service providers; liability for use of content; price reductions; Allscripts ability to license and integrate third party technologies; Allscripts ability to maintain or expand its business with existing customers; risks related to international operations; changes in tax rates or laws; business disruptions; Allscripts ability to maintain proper and effective internal controls; and asset and long-term investment impairment charges. The following discussion should be read in conjunction with the unaudited consolidated financial statements and notes thereto included in Part I, Item 1, "Financial Statements (unaudited)" in this Form 10-Q, as well as our Form 10-K filed with the Securities and Exchange Commission (the "SEC"). We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.*

*Each of the terms "we," "us," "our" or "Company" as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and/or its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.*

### **Overview**

#### ***Our Business Overview and Regulatory Environment***

We deliver information technology ("IT") solutions and services to help healthcare organizations achieve optimal clinical, financial and operational results. We sell our solutions to physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, and post-acute organizations, such as home health and hospice agencies. We help our clients improve the quality and efficiency of health care with solutions that include electronic health records ("EHRs"), connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support and population health management.

Our solutions empower healthcare professionals with the data, insights and connectivity to other caregivers they need to succeed in an industry that is rapidly changing from fee-for-service models to fee-for-value advanced payment models. We believe we offer some of the most comprehensive solutions in our industry today. Healthcare organizations can effectively manage patients and patient populations across all care settings using a combination of our physician, hospital, health system, post-acute care and population health management products and services. We believe these solutions will help transform health care as the industry seeks new ways to manage risk, improve quality and reduce costs.

Globally, healthcare providers face an aging population and the challenge of caring for an increasing number of patients with chronic diseases. At the same time, practitioners worldwide are also under growing pressure to demonstrate the delivery of high-quality care at lower costs. Population health management, analytics, connectivity based on open Application Programming Interfaces (“APIs”), and patient engagement are strategic imperatives that can help address these challenges. In the United States, for example, such initiatives will be critical tools for success under the framework of the Quality Payment Program (“QPP”), launched by the Centers for Medicare & Medicaid Services (“CMS”) in response to the passage of the Medicare Access and CHIP Reauthorization Act (“MACRA”). As healthcare providers and payers migrate from volume-based to value-based care delivery, interoperable solutions that are connected to the consumer marketplace are the key to market leadership in the new healthcare reality. Additionally, there is a small but growing portion of the market interested in payment models not reliant on insurance, such as the direct primary care model, with doctors and other healthcare professionals interested in the clinical value of the interoperable EHR separate and apart from payment mechanisms established by public or commercial payers or associated reporting requirements.

We believe our solutions are delivering value to our clients by providing them with powerful connectivity, as well increasingly robust patient engagement and care coordination tools, enabling users to successfully participate in alternative payment models that reward high value care delivery. Population health management is commonly viewed as one of the critical next frontiers in healthcare delivery, and we expect this rapidly emerging area to be a key driver of our future growth, both domestically and globally.

Recent advances in molecular science and computer technology are creating opportunities for the delivery of personalized medicine solutions. We believe these solutions will transform the coordination and delivery of health care, ultimately improving patient outcomes.

Specific to the United States, the healthcare IT industry in which we operate is in the midst of a period of rapid evolution, primarily due to new laws and regulations, as well as changes in industry standards. Various incentives that exist today (including alternative payment models that reward high value care delivery) have been rapidly moving health care toward a time where EHRs are as common as practice management or other financial systems in all provider offices. As a result, we believe that legislation, such as the aforementioned MACRA, as well as other government-driven initiatives (including at the state level), will continue to affect healthcare IT adoption and expansion, including products and solutions like ours. We also believe that we are well-positioned in the market to take advantage of the ongoing opportunity presented by these changes.

Given that CMS has proposed further regulations which require use of EHRs and other health information technology, including payment rules for upcoming years, even as we comply with previously published rules, our industry is preparing for additional areas in which we must execute compliance. Similarly, our ability to achieve expanded applicable product certification requirements, the changing strategies related to the Office of the National Coordinator for Health Information Technology (“ONC”) certification program, and the length of related development and other efforts required to meet regulatory standards could materially impact our capacity to maximize the market opportunity. All of our market-facing EHR solutions and several other relevant products have successfully completed the testing process and are certified as 2015 Edition-compliant by an ONC-Authorized Certification Body. Allscripts remains committed to satisfying evolving certification requirements and meeting conditions of certification, including those that will be finalized at the end of the review process by ONC this year.

Use of the Medicare Sustainable Growth Rate reimbursement model ceased in 2015 with the passage of the MACRA. The MACRA further encouraged the adoption of health IT necessary to satisfy new requirements more closely associating the report of quality measurements to Medicare payments. Following the finalization of the rule for the QPP in 2017, providers accepting payment from Medicare were given an opportunity to select one of two payment models: The Merit-based Incentive Payment System (“MIPS”) or an Advanced Alternative Payment Model (“APM”). Both of these approaches require substantive reporting on quality measures; additionally, the MIPS consolidated several preexisting incentive programs, including Medicare Meaningful Use and Physician Quality Reporting System, under one umbrella, as required by statute. The implementation of this new law is likely driving additional interest in our products among providers who were not eligible for or chose not to participate in the Health Information Technology for Economic and Clinical Health Act (“HITECH”) incentive program but now see a new reason to adopt EHRs and other health information technologies or by those needing to purchase more robust systems to help comply with more complex MACRA requirements. Additional regulations continue to be released annually clarifying requirements related to reporting and quality measures, which will enable physician populations and healthcare organizations to make strategic decisions about the purchase of analytic software or other solutions important to comply with the new law and associated regulations.

HITECH resulted in additional related new orders for our EHR products, and we believe that the MACRA could drive purchases of not only EHRs but additional technologies necessary in advanced payment models. Large physician groups will continue to purchase and enhance their use of EHR technology; while the number of very large practices with over 100 physicians that have not yet acquired such technology is insignificant, those considering replacement purchases are increasing. Such practices may choose to replace older EHR technology in the future as regulatory requirements (such as those related to Advanced APMs) and business realities dictate the need for updates and upgrades, as well as additional features and functionality. As incentive payment strategies shift in policies under the current Presidential Administration in the United States, the role of commercial payers and their continued expansion of alternative payment models and interest in attaining larger volumes of clinical data, as well as the anticipated growth in Medicaid payment models, are expected to provide additional incentives for purchase and expansion.

We also continue to see activity in local community-based buying, whereby individual hospitals, health systems and integrated delivery networks subsidize the purchase of EHR licenses or related services for local, affiliated physicians and physicians across their employed physician base in order to leverage buying power and help those practices take advantage of payment reform opportunities. This activity has also resulted in a pull-through effect where smaller practices affiliated with a community hospital are motivated to participate in a variety of incentive programs, while the subsidizing health system expands connectivity within the local provider community. We believe that the 2013 extension of exceptions to the Stark Law and Anti-Kickback Statute, which allowed hospitals and other organizations to subsidize the purchase of EHRs, will continue to contribute to the growth of this market dynamic, and we await announced regulatory revisions from HHS that are expected to further support value-based payment models and their associated purchasing arrangements between hospitals and physician practices. We also believe that new orders driven by the MACRA legislation and related to EHR and community-based activity may continue to come in as physicians in those small- and medium-sized practices seek to avoid payment adjustments stemming from the QPP or programs implemented by commercial payers. The associated challenge we face is to successfully position, sell, implement and support our products to hospitals, health systems or integrated delivery networks that subsidize their affiliated physicians. We believe the community programs we have in place will help us penetrate these markets.

We believe we have taken and continue to take the proper steps to maximize the opportunity presented by the QPP and other new payment programs, including several announced recently, such as Primary Care First and the *Pathways to Success* overhaul of Medicare's National ACO program. However, given the effects the laws are having on our clients, there can be no assurance that they will result in significant new orders for us in the near term, and if they do, that we will have the capacity to meet the additional market demand in a timely fashion.

Additionally, other public laws to reform the United States healthcare system contain various provisions which may impact us and our clients. Continued efforts by the current Presidential Administration and Congress to alter aspects of the Patient Protection and Affordable Care Act (as amended, the "PPACA") create uncertainty for us and for our clients, particularly as it relates to funding of the cost sharing subsidies. Some laws currently in place may have a positive impact by requiring the expanded use of EHRs, quality measurement, prescription drug monitoring and analytics tools to participate in certain federal, state or private sector programs. Others, such as adjustments made to the PPACA by the current Presidential Administration and Congress, laws or regulations mandating reductions in reimbursement for certain types of providers, decreasing insurance coverage of patients, state level requests for waivers from CMS related to Medicaid modeling, or increasing regulatory oversight of our products or our business practices, may have a negative impact by reducing the resources available to purchase our products. Increases in fraud and abuse enforcement and payment adjustments for non-participation in certain programs or overpayment of certain incentive payments may also adversely affect participants in the healthcare sector, including us.

Generally, Congressional oversight of EHRs and health information technology increased in recent years, including a specific focus on perceived interoperability failures and physician frustration with user burden, as well as contributing factors to such dissatisfaction. This increased oversight could impact our clients and our business. The passage of the 21<sup>st</sup> Century Cures Act in December 2016 assuaged some concerns about interoperability and possible FDA oversight of EHRs, and we are participating in the review and comment process for the regulations on data blocking and interoperability that were released by HHS in February 2019. We will respond as necessary to the finalized regulations on those topics, expected by year's end.

Congressional focus on addressing the opioid epidemic in part through technological applications and reducing clinician burden is likely to continue. The Administration is also taking action in some areas that may directly or indirectly affect Allscripts and our clients, including efforts to increase health-related price transparency in order to support patients in applying market-based pressures to the nation's challenge of cost containment. Further, CMS has proposed changes to the Evaluation & Management coding structure that ties closely to our clients' requirements to document the care they are delivering prior to payment. We expect these changes may have a positive effect on clinician satisfaction with our EHRs, if implemented as proposed, though the fundamentals of payment will remain in transition to value-based payment models.

New payment and delivery system reform programs, including those related to the Medicare program, are increasingly being rolled out at the state level through Medicaid administrators, as well as through the private sector, presenting additional opportunities for us to provide software and services to our clients who participate.

We derive our revenues primarily from sales of our proprietary software (either as a perpetual license sale or under a subscription delivery model), support and maintenance services, and managed services, such as outsourcing, private cloud hosting and revenue cycle management.

#### ***Critical Accounting Policies and Estimates***

We adopted the new leasing standard ASU 2016-02 effective January 1, 2019. The standard requires that leased assets and corresponding lease liabilities be recognized in the consolidated balance sheets as right-to-use assets and operating or financing lease liabilities. Refer to Note 3 "Leases" to our consolidated financial statements included Part I, Item 1, "Financial Statements (unaudited)" of this Form 10-Q for further information regarding the impact of adopting ASU 2016-02.

There were no other material changes to our critical accounting policies and estimates from those previously disclosed in our Form 10-K.

### *First Quarter 2019 Summary*

During the first quarter of 2019, we continued to make incremental progress on our key strategic, financial and operational imperatives aimed at driving higher client satisfaction, improving our competitive position by expanding the depth and breadth of our products and integrating recent acquisitions. Additionally, we believe there are still opportunities to continue to improve our operating leverage and further streamline our operations and such efforts are ongoing.

Total revenue for the first quarter of 2019 was \$432 million, a decrease of \$1.7 million compared to the first quarter of 2018. For the three months ended March 31, 2019, software delivery, support and maintenance revenue and client services revenue was \$275 and \$157 million, respectively, compared with \$281 million and \$153 million, respectively, during the three months ended March 31, 2018.

Gross profit and gross margin decreased during the three months ended March 31, 2019 compared with the prior year comparable period primarily due to the sale of the OneContent business during the three months ended June 30, 2018. The OneContent business was acquired as part of the EIS business acquisition on October 2, 2017 and had a higher gross margin compared with our other businesses. Gross profit and gross margin also decreased due to higher amortization of software development and acquisition-related assets driven by additional amortization expense associated with intangible assets acquired as part of recent acquisition. Gross profit margin was 40.3% during the three months ended March 31, 2019 compared with 42.6% during the three months ended March 31, 2018.

Our contract backlog as of March 31, 2019 was \$4 billion, an increase compared with our contract backlog of \$3.9 billion as of December 31, 2018, while decreasing compared with contract backlog as of March 31, 2018 of \$4.3 billion.

Our bookings, which reflect the value of executed contracts for software, hardware, other client services, private-cloud hosting, outsourcing and subscription-based services, totaled \$286 million for the three months ended March 31, 2019, which represents an increase of 9% over the comparable prior period amount of \$263 million and a decrease of 3% from the fourth quarter of 2018 amount of \$295 million.

## Overview of Consolidated Results

Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

| (In thousands)  | Three Months Ended March 31, |                    |          |
|---|------------------------------|--------------------|----------|
|   | 2019                         | 2018               | % Change |
| <b>Revenue:</b>   |                              |                    |          |
| Software delivery, support and maintenance  | \$ 275,512                   | \$ 280,553         | (1.8%)   |
| Client services   | 156,537                      | 153,169            | 2.2%     |
| Total revenue   | <u>432,049</u>               | <u>433,722</u>     | (0.4%)   |
| <b>Cost of revenue:</b>   |                              |                    |          |
| Software delivery, support and maintenance  | 88,133                       | 86,010             | 2.5%     |
| Client services   | 141,599                      | 137,088            | 3.3%     |
| Amortization of software development and acquisition-related assets   | 28,222                       | 25,959             | 8.7%     |
| Total cost of revenue   | <u>257,954</u>               | <u>249,057</u>     | 3.6%     |
| Gross profit  | 174,095                      | 184,665            | (5.7%)   |
| Gross margin %  | 40.3%                        | 42.6%              |          |
| Selling, general and administrative expenses  | 100,245                      | 119,937            | (16.4%)  |
| Research and development  | 64,310                       | 64,790             | (0.7%)   |
| Asset impairment charges  | 98                           | 0                  | NM       |
| Amortization of intangible and acquisition-related assets   | 6,797                        | 6,639              | 2.4%     |
| Income (loss) from operations   | 2,645                        | (6,701)            | (139.5%) |
| Interest expense  | (10,184)                     | (11,694)           | (12.9%)  |
| Other income (loss), net  | 513                          | (35)               | NM       |
| Loss on sale of businesses, net   | 0                            | (871)              | (100.0%) |
| Recovery (impairment) of long-term investments  | 1,045                        | (5,500)            | (119.0%) |
| Equity in net loss of unconsolidated investments  | (64)                         | (61)               | 4.9%     |
| Loss from continuing operations before income taxes   | (6,045)                      | (24,862)           | (75.7%)  |
| Income tax provision  | (1,932)                      | (299)              | NM       |
| Effective tax rate  | (32.0%)                      | (1.2%)             |          |
| Loss from continuing operations, net of tax   | <u>(7,977)</u>               | <u>(25,161)</u>    | (68.3%)  |
| Loss from discontinued operations   | 0                            | (5,016)            | (100.0%) |
| Income tax effect on discontinued operations  | 0                            | 1,662              | (100.0%) |
| Loss from discontinued operations, net of tax   | <u>0</u>                     | <u>(3,354)</u>     | (100.0%) |
| Net loss  | (7,977)                      | (28,515)           | (72.0%)  |
| Net loss attributable to non-controlling interest   | 424                          | 790                | (46.3%)  |
| Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations | 0                            | (12,149)           | (100.0%) |
| Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders                                     | <u>\$ (7,553)</u>            | <u>\$ (39,874)</u> | (81.1%)  |

NM – We define “NM” as not meaningful for increases or decreases greater than 200%.



## Revenue

| (In thousands)        | Three Months Ended March 31, |            |          |
|-----------------------|------------------------------|------------|----------|
|                       | 2019                         | 2018       | % Change |
| Revenue:              |                              |            |          |
| Recurring revenue     | \$ 348,636                   | \$ 352,660 | (1.1%)   |
| Non-recurring revenue | 83,413                       | 81,062     | 2.9%     |
| Total revenue         | \$ 432,049                   | \$ 433,722 | (0.4%)   |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Recurring revenue consists of subscription-based software sales, support and maintenance revenue, recurring transactions revenue, and recurring revenue from managed services solutions, such as outsourcing, private cloud hosting and revenue cycle management. Non-recurring revenue consists of perpetual software licenses sales, hardware resale and non-recurring transactions revenue, and project-based client services revenue.

The decrease in recurring revenue was primarily driven by the sale of the OneContent business on April 2, 2018. The OneContent business was acquired as part of the EIS business acquisition on October 2, 2017. The OneContent business contributed \$13 million of recurring revenue during the three months ended March 31, 2018, including \$1 million of amortization of acquisition-related deferred revenue adjustments. This decrease was partly offset by additional revenue from the acquisitions of Practice Fusion and Health Grid during 2018 and higher demand for managed services solutions across our customer base. Non-recurring revenue increased primarily as a result of higher sales of perpetual software license for our acute solutions as the current quarter included several large transactions which did not recur in the prior year quarter. This increase was partly offset by a net decrease in non-recurring revenue as a result of the above noted disposition and acquisitions and lower client services revenue related to a decrease in upgrade activity.

The percentage of recurring and non-recurring revenue of our total revenue was 81% and 19%, respectively, during both the three months ended March 31, 2019 and 2018.

## Gross Profit

| (In thousands)        | Three Months Ended March 31, |            |          |
|-----------------------|------------------------------|------------|----------|
|                       | 2019                         | 2018       | % Change |
| Total cost of revenue | \$ 257,954                   | \$ 249,057 | 3.6%     |
| Gross profit          | \$ 174,095                   | \$ 184,665 | (5.7%)   |
| Gross margin %        | 40.3%                        | 42.6%      |          |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Gross profit and gross margin decreased during the three months ended March 31, 2019 compared with the prior year comparable period primarily due to the sale of the OneContent business, which had a higher gross margin compared with our other businesses. Gross profit and gross margin also decreased due to higher amortization of software development and acquisition-related assets driven by additional amortization expense associated with intangible assets acquired as part of recent acquisitions.

## Selling, General and Administrative Expenses

| (In thousands)                               | Three Months Ended March 31, |            |          |
|--|------------------------------|------------|----------|
|  | 2019                         | 2018       | % Change |
| Selling, general and administrative expenses | \$ 100,245                   | \$ 119,937 | (16.4%)  |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Selling, general and administrative expenses decreased during the three months ended March 31, 2019 compared with the prior year comparable period, primarily due to lower severance and incentive compensation costs driven by headcount reduction actions taken during 2018 as part of the integration of the EIS, Practice Fusion and Health Grid acquisitions, and lower transaction-related and legal expenses.

## Research and Development

| (In thousands)           | Three Months Ended March 31, |           |          |
|--------------------------|------------------------------|-----------|----------|
|                          | 2019                         | 2018      | % Change |
| Research and development | \$ 64,310                    | \$ 64,790 | (0.7%)   |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Research and development expenses remained flat during the three months ended March 31, 2019 compared with the prior year comparable period as additional expenses from recent acquisitions were mitigated by our continued efforts to streamline our operations, improve operational efficiency and integrate these acquisitions as well as higher capitalized software development costs. Research and development expenses can also fluctuate from changes in the level of capitalized software development costs. The capitalization of software development costs is highly dependent on the nature of the work being performed and the development status of projects and, therefore, it is common for the amount of capitalized software development costs to fluctuate.

## Asset Impairment Charges

| (In thousands)           | Three Months Ended March 31, |      |          |
|--------------------------|------------------------------|------|----------|
|                          | 2019                         | 2018 | % Change |
| Asset impairment charges | \$ 98                        | \$ 0 | NM       |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Asset impairment charges for the three months ended March 31, 2019 were the result of miscellaneous fixed asset write-offs.

## Amortization of Intangible Assets

| (In thousands)  | Three Months Ended March 31, |          |          |
|---|------------------------------|----------|----------|
|   | 2019                         | 2018     | % Change |
| Amortization of intangible and acquisition-related assets | \$ 6,797                     | \$ 6,639 | 2.4%     |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

The increase in amortization expense for the three months ended March 31, 2019 compared with the prior year comparable period was due to incremental amortization expense associated with intangible assets acquired as part of business combinations completed during 2018.

## Interest Expense

| (In thousands)   | Three Months Ended March 31, |           |          |
|------------------|------------------------------|-----------|----------|
|                  | 2019                         | 2018      | % Change |
| Interest expense | \$ 10,184                    | \$ 11,694 | (12.9%)  |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Interest expense during the three months ended March 31, 2019 decreased compared to the prior year comparable period due to the impact of lower average outstanding borrowings partially offset by higher interest rates.

## Other Income (Loss), Net

| (In thousands)           | Three Months Ended March 31, |         |          |
|--------------------------|------------------------------|---------|----------|
|                          | 2019                         | 2018    | % Change |
| Other income (loss), net | \$ 513                       | \$ (35) | NM       |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Other income (loss), net for the three months ended March 31, 2019 and 2018 consisted of a combination of interest income, and miscellaneous receipts and expenses.

## Loss on Sale of Businesses, Net

| (In thousands)                  | Three Months Ended March 31, |          |          |
|---------------------------------|------------------------------|----------|----------|
|                                 | 2019                         | 2018     | % Change |
| Loss on sale of businesses, net | \$ 0                         | \$ (871) | (100.0%) |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Loss on sale of businesses, net during the three months ended March 31, 2018 relates to the divestiture of our Strategic Sourcing business.

### Recovery (Impairment) of Long-term investments

| (In thousands)                                 | Three Months Ended March 31, |            |          |
|--|------------------------------|------------|----------|
|  | 2019                         | 2018       | % Change |
| Recovery (impairment) of long-term investments | \$ 1,045                     | \$ (5,500) | (119.0%) |

Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

During the three months ended March 31, 2019, we recovered \$1.0 million from a third-party cost-method investment that we had previously impaired. The impairment charges for the three months ended March 31, 2018 related to one of our other cost method equity investments and a related note receivable.

### Equity in Net (Loss) Income of Unconsolidated Investments

| (In thousands)                                   | Three Months Ended March 31, |         |          |
|--|------------------------------|---------|----------|
|  | 2019                         | 2018    | % Change |
| Equity in net loss of unconsolidated investments | \$ (64)                      | \$ (61) | 4.9%     |

Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Equity in net loss of unconsolidated investments represents our share of the equity earnings (losses) of our investments in third parties accounted for under the equity method of accounting.

### Income Taxes

| (In thousands)       | Three Months Ended March 31, |          |          |
|----------------------|------------------------------|----------|----------|
|                      | 2019                         | 2018     | % Change |
| Income tax provision | \$ (1,932)                   | \$ (299) | NM       |

Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

The United States Tax Cuts and Jobs Act (the "Tax Act") was enacted on December 22, 2017 and introduced significant changes to the income tax law in the United States. Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to permanent differences, income attributable to foreign jurisdictions taxed at different rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three months ended March 31, 2019, compared with the prior year comparable period, differs primarily due to higher tax shortfalls associated with stock-based compensation reflected in the provision for the three months ended March 31, 2019 and valuation allowance of \$10.7 million recorded in the three months ended March 31, 2018.

In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). During the three months ended March 31, 2019, we recorded immaterial impacts for valuation allowances.

### Discontinued Operations

| (In thousands)                               | Three Months Ended March 31, |            |          |
|--|------------------------------|------------|----------|
|  | 2019                         | 2018       | % Change |
| Loss from discontinued operations            | \$ 0                         | \$ (5,016) | (100.0%) |
| Income tax effect on discontinued operations | \$ 0                         | \$ 1,662   | (100.0%) |

Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

On December 31, 2018, we sold all of the Class A Common Units of Netsmart owned by the Company. Prior to the sale, Netsmart comprised a separate reportable segment, which due to its significance to our historical consolidated financial statements and results of operations, is now reported as a discontinued operation as a result of the sale for all periods presented. The loss from discontinued operations primarily represents the net losses incurred by Netsmart for the three ended March 31, 2018. Also included in discontinued operations are earnings associated with the Horizon Clinicals and Series2000 Revenue Cycle product offerings, which we stopped supporting effective as of March 31, 2018. Refer to Note 14, "Discontinued Operations" of the Notes to Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for further information regarding discontinued operations.

### Non-Controlling Interests

| (In thousands)  | Three Months Ended March 31, |             |          |
|---|------------------------------|-------------|----------|
|   | 2019                         | 2018        | % Change |
| Net loss attributable to non-controlling interest   | \$ 424                       | \$ 790      | (46.3%)  |
| Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations | \$ 0                         | \$ (12,149) | (100.0%) |

Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

The net loss attributable to non-controlling interest represents the share of earnings of consolidated affiliates that is attributable to the affiliates' common stock that is not owned by us for each of the periods presented. The accretion of redemption preference on redeemable convertible non-controlling interest represents the accretion of liquidation preference at 11% per annum to the value of the preferred units of Netsmart prior to the sale of our investment in Netsmart on December 31, 2018.

**Segment Operations**

During the first quarter of 2019, we changed our reportable segments from Clinical and Financial Solutions, Population Health and Unallocated to Provider, Veradigm and Unallocated. The segment disclosures below for the three months ended March 31, 2018, have been revised to conform to the current year presentation. Refer to Note 15 "Business Segments" of the Notes to Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for further discussion on the impact of the change.

*Overview of Segment Results*

| (In thousands)                             | Three Months Ended March 31, |                   |                 |
|--|------------------------------|-------------------|-----------------|
|  | 2019                         | 2018              | % Change        |
| <b>Revenue:</b>                            |                              |                   |                 |
| Provider                                   | \$ 392,607                   | \$ 410,424        | (4.3%)          |
| Veradigm                                   | 35,116                       | 22,807            | 54.0%           |
| Unallocated Amounts                        | 4,326                        | 491               | NM              |
| <b>Total revenue</b>                       | <b>\$ 432,049</b>            | <b>\$ 433,722</b> | <b>(0.4%)</b>   |
| <b>Gross Profit:</b>                       |                              |                   |                 |
| Provider                                   | \$ 165,818                   | \$ 185,729        | (10.7%)         |
| Veradigm                                   | 22,434                       | 15,130            | 48.3%           |
| Unallocated Amounts                        | (14,157)                     | (16,194)          | (12.6%)         |
| <b>Total gross profit</b>                  | <b>\$ 174,095</b>            | <b>\$ 184,665</b> | <b>(5.7%)</b>   |
| <b>Income (loss) from operations:</b>      |                              |                   |                 |
| Provider                                   | \$ 100,274                   | \$ 107,140        | (6.4%)          |
| Veradigm                                   | 8,319                        | 5,032             | 65.3%           |
| Unallocated Amounts                        | (105,948)                    | (118,873)         | (10.9%)         |
| <b>Total income (loss) from operations</b> | <b>\$ 2,645</b>              | <b>\$ (6,701)</b> | <b>(139.5%)</b> |

## Provider

Our Provider segment derives its revenue from the sale of integrated clinical software applications, financial management and patient engagement solutions, which primarily include EHR-related software, connectivity and coordinated care solutions, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training and electronic claims administration services.

| (In thousands)         | Three Months Ended March 31, |            |          |
|------------------------|------------------------------|------------|----------|
|                        | 2019                         | 2018       | % Change |
| Revenue                | \$ 392,607                   | \$ 410,424 | (4.3%)   |
| Gross profit           | \$ 165,818                   | \$ 185,729 | (10.7%)  |
| Gross margin %         | 42.2%                        | 45.3%      |          |
| Income from operations | \$ 100,274                   | \$ 107,140 | (6.4%)   |
| Operating margin %     | 25.5%                        | 26.1%      |          |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Provider revenue, gross profit and income from operations decreased during the three months ended March 31, 2019 compared with the prior year comparable periods, primarily as a result of the sale of the OneContent and Strategic Sourcing businesses on March 15, 2018 and on April 2, 2018, respectively. These businesses were acquired as part of the EIS business acquisition on October 2, 2017 and contributed \$16 million of revenue during the three months ended March 31, 2018, including \$1 million of amortization of acquisition-related deferred revenue adjustments. The remainder of the decrease in revenue was primarily driven by lower recurring software delivery, support and maintenance revenue and lower non-recurring client services revenue, which were partly offset by higher non-recurring software delivery, support and maintenance revenue and higher recurring client services revenue. The decrease in non-recurring client services revenue was primarily related to a decrease in upgrade activity. The increase in non-recurring software delivery, support and maintenance revenue was driven by higher sales of perpetual software licenses for our acute solutions as the current quarter included several large transactions which did not recur in the prior year quarter. The increase in recurring client services revenue was primarily driven by higher demand for managed services solutions across our customer base.

Gross margin and operating margin decreased during the three months ended March 31, 2019 compared with the prior year comparable period primarily due to the sale of the OneContent business, which had higher overall profitability compared with our other Provider businesses. The decrease in the operating margin was partly offset by favorability from lower selling, general and administrative, and research and development expenses driven by headcount reduction actions taken during 2018 as part of the integration of the EIS, Practice Fusion and Health Grid acquisitions.

## Veradigm

Our Veradigm segment derives its revenue from the provision of data-driven clinical insights with actionable tools for clinical workflow, research, analytics and media. Its solutions, targeted at key healthcare stakeholders, help improve the quality, efficiency and value of healthcare delivery – from biopharma to health plans, healthcare providers and patients, and health technology partners, among others.

| (In thousands)         | Three Months Ended March 31, |           |          |
|------------------------|------------------------------|-----------|----------|
|                        | 2019                         | 2018      | % Change |
| Revenue                | \$ 35,116                    | \$ 22,807 | 54.0%    |
| Gross profit           | \$ 22,434                    | \$ 15,130 | 48.3%    |
| Gross margin %         | 63.9%                        | 66.3%     |          |
| Income from operations | \$ 8,319                     | \$ 5,032  | 65.3%    |
| Operating margin %     | 23.7%                        | 22.1%     |          |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Veradigm revenue, gross profit and income from operations increased during the three months ended March 31, 2019 compared with the prior year comparable period, primarily driven by the acquisition of Practice Fusion during the second quarter of 2018 as well as organic growth. The three-month period ended March 31, 2018, includes only a partial quarter of Practice Fusion's results.

Gross margin decreased during the three months ended March 31, 2019 compared with the prior year comparable period, primarily due to higher internal and external costs incurred to support the growth of this segment. Operating margin improved during the three months ended March 31, 2019 compared with the prior year comparable period, primarily due to improved operating leverage as overall selling, general and administrative expenses increased at a lower rate than the growth in revenue and gross profit, and decreased as a percentage of revenue.

### Unallocated Amounts

In determining revenue, gross profit and income from operations for our segments, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in a business acquisition. We also exclude the amortization of intangible assets, stock-based compensation expense, expenses not reflective of our core business and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Expenses not reflective of our core business relate to certain severance, product consolidation, legal, consulting and other charges. Accordingly, these amounts are not included in our reportable segment results and are included in the “Unallocated Amounts” category. The “Unallocated Amounts” category also includes (i) corporate general and administrative expenses (including marketing expenses) and certain research and development expenses related to common solutions and resources that benefit all of our business units, all of which are centrally managed, and (ii) revenue and the associated cost from the resale of certain ancillary products, primarily hardware.

| (In thousands)       | Three Months Ended March 31, |              |          |
|----------------------|------------------------------|--------------|----------|
|                      | 2019                         | 2018         | % Change |
| Revenue              | \$ 4,326                     | \$ 491       | NM       |
| Gross profit         | \$ (14,157)                  | \$ (16,194)  | (12.6%)  |
| Gross margin %       | NM                           | NM           |          |
| Loss from operations | \$ (105,948)                 | \$ (118,873) | (10.9%)  |
| Operating margin %   | NM                           | NM           |          |

#### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Revenue from the resale of ancillary products, primarily consisting of hardware, is customer and project driven and, as a result, can fluctuate from period to period. Revenue for the three months ended March 31, 2019 increased compared with the prior year comparable period due to an increase in hardware revenue in other products as well as only \$0.6 million in amortization of acquisition-related deferred revenue adjustments that was recorded during the three months ended March 31, 2019 compared to \$3.9 million during the three months ended March 31, 2018. The acquisition-related adjustments primarily resulted from the acquisitions of the EIS business as well as Practice Fusion.

Gross unallocated expenses, which represent the unallocated loss from operations excluding the impact of revenue, totaled \$110 million for the three months ended March 31, 2019 compared with \$119 million for the prior year comparable period. The decrease for the three months ended March 31, 2019 compared with the comparable prior year period was primarily driven by (i) lower amortization of acquired intangible assets of \$3 million, (ii) lower transaction-related, severance and legal expenses of \$12 million, and (iii) offset with an increase in stock-based compensation of \$2 million.

### Contract Backlog

Contract backlog represents the value of bookings and support and maintenance contracts that have not yet been recognized as revenue. A summary of contract backlog by revenue category is as follows:

| (In millions)                              | % Change vs. March 31, 2019 |                         |                      |                   |                |
|--|-----------------------------|-------------------------|----------------------|-------------------|----------------|
|  | As of March 31, 2019        | As of December 31, 2018 | As of March 31, 2018 | December 31, 2018 | March 31, 2018 |
| Software delivery, support and maintenance | \$ 2,717                    | \$ 2,507                | \$ 2,602             | 8.4%              | 4.4%           |
| Client services                            | 1,324                       | 1,350                   | 1,675                | (1.9%)            | (21.0%)        |
| Total contract backlog                     | \$ 4,041                    | \$ 3,857                | \$ 4,277             | 4.8%              | (5.5%)         |

Total contract backlog as of March 31, 2019 was increased compared with December 31, 2018 and decreased compared with March 31, 2018. Total contract backlog can fluctuate between periods based on the level of revenue and bookings as well as the timing and mix of renewal activity and periodic revalidations.

## Liquidity and Capital Resources

The primary factors that influence our liquidity include, but are not limited to, the amount and timing of our revenues, cash collections from our clients, capital expenditures and investments in research and development efforts, including investments in or acquisitions of third-parties. As of March 31, 2019, our principal sources of liquidity consisted of cash and cash equivalents of \$148 million and available borrowing capacity of \$899 million under our revolving credit facility. The change in our cash and cash equivalents balance is reflective of the following:

### Operating Cash Flow Activities

| (In thousands)  | Three Months Ended March 31, |             |             |
|---|------------------------------|-------------|-------------|
|   | 2019                         | 2018        | \$ Change   |
| Net loss  | \$ (7,977)                   | \$ (28,515) | \$ 20,538   |
| Less: Loss from discontinued operations                                       | 0                            | (3,354)     | 3,354       |
| Loss from continuing operations   | (7,977)                      | (25,161)    | 17,184      |
| Non-cash adjustments to net income  | 66,399                       | 64,119      | 2,280       |
| Cash impact of changes in operating assets and liabilities                    | (22,606)                     | 15,357      | (37,963)    |
| Net cash provided by operating activities - continuing operations             | 35,816                       | 54,315      | (18,499)    |
| Net cash (used in) provided by operating activities - discontinued operations | (30,000)                     | 3,993       | (33,993)    |
| Net cash provided by operating activities                                     | \$ 5,816                     | \$ 58,308   | \$ (52,492) |

Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Net cash provided by operating activities decreased during the three months ended March 31, 2019 compared with the prior year comparable period primarily due to working capital changes and higher incentive compensation payments. Non-cash adjustments to net loss increased slightly during the three months ended March 31, 2019 compared with prior year comparable period. Higher depreciation and amortization expenses, primarily driven by the amortization of operating right-to-use assets, and stock-based compensation were partly offset by a recovery of previously impaired cost method investment in the current quarter and no impairments of long-term investments during the three months ended March 31, 2019 as compared to the prior year comparable period.

Net cash used in operating activities – discontinued operations during the three months ended March 31, 2019 reflects an advance income tax payment related to the gain realized upon the sale of our investment in Netsmart on December 31, 2018.

### Investing Cash Flow Activities

| (In thousands)  | Three Months Ended March 31, |              |            |
|---|------------------------------|--------------|------------|
|   | 2019                         | 2018         | \$ Change  |
| Capital expenditures  | \$ (4,847)                   | \$ (7,508)   | \$ 2,661   |
| Capitalized software  | (28,600)                     | (26,168)     | (2,432)    |
| Cash paid for business acquisitions, net of cash acquired                       | 0                            | (107,212)    | 107,212    |
| Purchases of equity securities, other investments and related intangible assets | 32                           | 0            | 32         |
| Other proceeds from investing activities  | 5                            | 37           | (32)       |
| Net cash used in investing activities - continuing operations                   | (33,410)                     | (140,851)    | 107,441    |
| Net cash used in investing activities - discontinued operations                 | 0                            | (8,961)      | 8,961      |
| Net cash used in investing activities   | \$ (33,410)                  | \$ (149,812) | \$ 116,402 |

Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

Net cash used in investing activities decreased during the three months ended March 31, 2019 compared with the prior year comparable period, primarily due to the acquisition of Practice Fusion during the three months ended March 31, 2018.

## Financing Cash Flow Activities

| (In thousands)  | Three Months Ended March 31, |           |             |
|---|------------------------------|-----------|-------------|
|   | 2019                         | 2018      | \$ Change   |
| Proceeds from sale or issuance of common stock                              | \$ 0                         | \$ 212    | \$ (212)    |
| Taxes paid related to net share settlement of equity awards                 | (5,327)                      | (8,496)   | 3,169       |
| Payments on debt instruments and lease obligations                          | (5,055)                      | (255)     | (4,800)     |
| Credit facility borrowings, net of issuance costs                           | 120,000                      | 145,843   | (25,843)    |
| Repurchase of common stock  | (65,070)                     | (57,599)  | (7,471)     |
| Payment of acquisition financing obligations                                | 0                            | (3,226)   | 3,226       |
| Purchases of subsidiary shares owned by non-controlling interest            | (54,064)                     | 0         | (54,064)    |
| Net cash (used in) provided by financing activities - continuing operations | (9,516)                      | 76,479    | (85,995)    |
| Net cash used in financing activities - discontinued operations             | 0                            | (3,766)   | 3,766       |
| Net cash (used in) provided by financing activities                         | \$ (9,516)                   | \$ 72,713 | \$ (82,229) |

### Three Months Ended March 31, 2019 Compared with the Three Months Ended March 31, 2018

During the three months ended March 31, 2019 we had net use of cash from financing activities compared with net cash provided from financing activities during the three months ended March 31, 2018. During the three months ended March 31, 2019, we purchased all of the outstanding minority interest in Pulse8, Inc., repurchased a higher amount of our common stock and had lower net credit facility borrowings compared with three months ended March 31, 2018.

### Future Capital Requirements

The following table summarizes our required minimum future payments under the 1.25% Notes and the Senior Secured Credit Facility as of March 31, 2019.

| (In thousands)                          | Total      | Remainder of 2019 | 2020       | 2021      | 2022      | 2023       | Thereafter |
|---|------------|-------------------|------------|-----------|-----------|------------|------------|
| <b>Principal payments:</b>              |            |                   |            |           |           |            |            |
| 1.25% Cash Convertible Senior Notes (1) | \$ 345,000 | \$ 0              | \$ 345,000 | \$ 0      | \$ 0      | \$ 0       | \$ 0       |
| Senior Secured Credit Facility (2)      | 465,000    | 15,000            | 27,500     | 30,000    | 37,500    | 355,000    | 0          |
| Total principal payments                | 810,000    | 15,000            | 372,500    | 30,000    | 37,500    | 355,000    | 0          |
| <b>Interest payments:</b>               |            |                   |            |           |           |            |            |
| 1.25% Cash Convertible Senior Notes (1) | 6,469      | 2,156             | 4,313      | 0         | 0         | 0          | 0          |
| Senior Secured Credit Facility (2) (3)  | 52,511     | 10,666            | 13,737     | 13,003    | 12,206    | 2,899      | 0          |
| Total interest payments                 | 58,980     | 12,822            | 18,050     | 13,003    | 12,206    | 2,899      | 0          |
| Total future debt payments              | \$ 868,980 | \$ 27,822         | \$ 390,550 | \$ 43,003 | \$ 49,706 | \$ 357,899 | \$ 0       |

(1) Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

(2) Assumes no additional borrowings after March 31, 2019, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

(3) Assumes LIBOR plus the applicable margin remain constant at the rate in effect on March 31, 2019, which was 4.50%.

### Other Matters Affecting Future Capital Requirements

Our total investment in research and development efforts during 2019 is expected to increase compared with 2018 as we continue to build and expand the capabilities and functionality of our traditional ambulatory, acute and post-acute platforms as well as those of Veradigm and our consumer health offerings. Our total spending consists of research and development costs directly recorded to expense which are offset by the capitalization of eligible development costs.



To supplement our statement of operations, the table below presents a non-GAAP measure of research and development-related expenses that we believe is a useful metric for evaluating how we are investing in research and development.

| (In thousands)  | Three Months Ended March 31, |            |
|---|------------------------------|------------|
|   | 2019                         | 2018       |
| Research and development costs directly recorded to expense                     | \$ 64,310                    | \$ 64,790  |
| Capitalized software development costs per consolidated statement of cash flows | 28,600                       | 26,168     |
| Total non-GAAP R&D-related spending   | \$ 92,910                    | \$ 90,958  |
| Total revenue   | \$ 432,049                   | \$ 433,722 |
| Total non-GAAP R&D-related spending as a % of total revenue                     | 21.5%                        | 21.0%      |

We believe that our cash and cash equivalents of \$148 million as of March 31, 2019, our future cash flows, and our borrowing capacity under our Revolving Facility, taken together, provide adequate resources to meet future operating needs as well as scheduled payments of long-term debt. We cannot provide assurance that our actual cash requirements will not be greater than we expect as of the date of this Form 10-Q. We will, from time to time, consider the acquisition of, or investment in, complementary businesses, products, services and technologies, and the repurchase of our common stock under our 2018 stock repurchase program, each of which might impact our liquidity requirements or cause us to borrow under our Revolving Facility or issue additional equity or debt securities.

#### Contractual Obligations, Commitments and Off-Balance Sheet Arrangements

We have various contractual obligations, which are recorded as liabilities in our consolidated financial statements. During the three months ended March 31, 2019, there were no material changes, outside of the ordinary course of business, to our contractual obligations and purchase commitments previously disclosed in our Form 10-K.

#### Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our market risk disclosures set forth in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of our Form 10-K have not changed materially during the three months ended March 31, 2019.

#### Item 4. Controls and Procedures

##### *Evaluation of Disclosure Controls and Procedures*

Under the direction of our chief executive officer and chief financial officer, we evaluated our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and concluded that our disclosure controls and procedures were effective as of March 31, 2019.

##### *Changes in Internal Control over Financial Reporting*

We have implemented, and continue to refine, internal controls related to the new leasing accounting standard which we adopted on January 1, 2019. There have been no other changes in our internal control over financial reporting during the quarter ended March 31, 2019, which were identified in connection with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II. OTHER INFORMATION

### Item 1. Legal Proceedings

We hereby incorporate by reference Note 13, "Contingencies," of the Notes to Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

### Item 1A. Risk Factors

Except as follows, there have been no material changes during the quarter ended March 31, 2019 from the risk factors as previously disclosed in our Form 10-K.

**The outcome of the government investigation of Practice Fusion or any future government investigations of our other businesses could have a material adverse effect on our business, financial condition and operating results.**

Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney's Office for the District of Vermont pursuant to a CID. Between April 2018 and January 2019, Practice Fusion received five additional requests for documents and information through another CID and HIPAA subpoenas. In March 2019, Practice Fusion received a grand jury subpoena in connection with a related criminal investigation. The document and information requests received by Practice Fusion relate to both the certification Practice Fusion obtained in connection with the U.S. Department of Health and Human Services' Electronic Health Record Incentive Program and Practice Fusion's compliance with the Anti-Kickback Statute and HIPAA as it relates to certain business practices engaged in by Practice Fusion. Practice Fusion continues to produce documents and information in response to these various requests. These matters or any future government investigations into our other businesses (or existing government investigation of our EIS business) could result in criminal liability, the imposition of damages, non-monetary relief, significant compliance, litigation or settlement costs, or any other losses. For example, we are aware of other EHR providers who are responding to similar investigations by the U.S. Attorney's Office, and two other EHR providers recently settled allegations by the Department of Justice that resulted from civil investigative demands and required significant payments and ongoing compliance costs in connection with long-term corporate integrity agreements. Similar settlements by or findings against us could have a material adverse effect on our business, financial condition and operating results.

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On August 2, 2018, we announced that our Board approved a new stock purchase program under which we may repurchase up to \$250 million of our common stock through December 31, 2020. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our 2018 stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

The following table summarizes the stock repurchase activity during the three months ended March 31, 2019 and the approximate dollar value of shares that may yet be purchased under our 2018 stock repurchase program:

(In thousands, except per share amounts)

| Period (Based on Trade Date) | Total<br>Number<br>Of Shares<br>Purchased | Average<br>Price<br>Paid Per<br>Share | Total Number<br>Of Shares<br>Purchased<br>As Part Of<br>Publicly<br>Announced<br>Plans Or<br>Programs | Approximate<br>Dollar Value<br>Of Shares<br>That May Yet<br>Be Purchased<br>Under The<br>Plans Or<br>Programs |
|------------------------------|---|---------------------------------------|---|---|
| 01/01/19—01/31/19            | 0   | \$ 0.00                               | 0   | \$ 213,050  |
| 02/01/19—02/28/19            | 500                                       | \$ 10.73                              | 500   | \$ 207,684  |
| 03/01/19—03/31/19            | 5,649                                     | \$ 10.55                              | 5,649   | \$ 148,104  |
|                              | <u>6,149</u>                              | \$ 10.56                              | <u>6,149</u>  |   |

**Item 6. Exhibits**

| <u>Exhibit Number</u> | <u>Exhibit Description</u>   | <u>Filed</u> | <u>Herewith</u> | <u>Furnished<br/>Herewith</u> |
|-----------------------|--|--------------|-----------------|-------------------------------|
| 31.1                  | <a href="#">Rule 13a - 14(a) Certification of Chief Executive Officer</a>                          |              | X               |                               |
| 31.2                  | <a href="#">Rule 13a - 14(a) Certification of Chief Financial Officer</a>                          |              | X               |                               |
| 32.1                  | <a href="#">Section 1350 Certifications of Chief Executive Officer and Chief Financial Officer</a> |              |                 | X                             |
| 101.INS               | XBRL Instance Document   |              | X               |                               |
| 101.SCH               | XBRL Taxonomy Extension Schema   |              | X               |                               |
| 101.CAL               | XBRL Taxonomy Extension Calculation Linkbase   |              | X               |                               |
| 101.LAB               | XBRL Taxonomy Extension Label Linkbase   |              | X               |                               |
| 101.PRE               | XBRL Taxonomy Extension Presentation Linkbase  |              | X               |                               |
| 101.DEF               | XBRL Taxonomy Definition Linkbase  |              | X               |                               |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

By:                                   /s/ Dennis M. Olis                                    
                                  **Dennis M. Olis**  
                                  **Chief Financial Officer**  
                                  **(Principal Financial and Accounting Officer)**

Date: May 3, 2019

**Certification**

I, Paul M. Black, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Allscripts Healthcare Solutions, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):
  - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 3, 2019

\_\_\_\_\_  
/s/ Paul M. Black  
Chief Executive Officer

**Certification**

I, Dennis M. Olis, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Allscripts Healthcare Solutions, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):
  - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 3, 2019

/s/ Dennis M. Olis  
Chief Financial Officer

**Exhibit 32.1**

The following statement is being made to the Securities and Exchange Commission solely for purposes of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), which carries with it certain criminal penalties in the event of a knowing or willful misrepresentation.

Securities and Exchange Commission  
100 F Street, NE  
Washington, D.C. 20549

Re: Allscripts Healthcare Solutions, Inc.

Ladies and Gentlemen:

In accordance with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 (18 USC 1350), each of the undersigned hereby certifies that:

- (i) this Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, which this statement accompanies, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
- (ii) the information contained in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, fairly presents, in all material respects, the financial condition and results of operations of Allscripts Healthcare Solutions, Inc.

Dated as of this 3<sup>rd</sup> day of May, 2019.

/s/ Paul M. Black

**Paul M. Black**  
**Chief Executive Officer**

/s/ Dennis M. Olis

**Dennis M. Olis**  
**Chief Financial Officer**

A signed original of this written statement required by Section 906 has been provided to Allscripts Healthcare Solutions, Inc. and will be retained by Allscripts Healthcare Solutions, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.